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ABSTRACT 
The leading cause of death worldwide is cardiovascular disease (CVD). Myocardial 
infarction (MI) (i.e., heart attack) makes up ~8.5% of CVD and is a common cause of heart 
failure with a 40% five-year mortality after the first MI. This highlights a substantial 
patient population and an urgent need to develop new therapeutic strategies (e.g., 
regenerative cell therapies). Moreover, this also indicates that current models may not 
sufficiently recapitulate human cardiac tissue. To date, drug development strategies have 
largely depended on high throughput 2D cell models and pre-clinical testing in animal 
models of MI leading to minimal improvements in the heart failure treatment paradigm 
over the past 20 years. Relevant human cardiac models would provide insight into human 
cardiac tissue physiology and maturation while also providing an advanced in vitro 
screening tool to explore heart failure pathogenesis. Cardiac tissue engineering has 
allowed for advances in the development of cardiac constructs by combining 
developments in biomaterials, 3D microtissue culture, and human induced pluripotent 
stem cells (hiPSC) technology. Notably, approaches that mimic the natural processes in 
the body (i.e., biomimetic) have led to further insight into cardiac physiology. Here, I have 
pursued biomimetic strategies to create a biomimetic model of human cardiac tissue 
using hiPSC-derived cardiomyocytes (hiPSC-CMs). Throughout this development, I 
explored the role of the matrix microenvironment on cell behavior using functionalized 
alginate, the influence of pacemaker-like exogenous electrical stimulation on the 
maturation of hiPSC-CM spheroids with endogenous electrically conductive 
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nanomaterials, and the development of vascularized, functional cardiac organoids by 
mimicking the coronary vasculogenesis stage of cardiac development. The research 
established here provided a biomimetic groundwork for future development into in vitro 
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THE NEED FOR BIOMIMETIC CARDIAC MODELS 
Introduction 
Cardiovascular disease is the leading cause of death and disability worldwide, claiming 
more lives than all types of cancers combined.1 Ischemic heart disease (IHD) and 
myocardial infarction (MI) are major contributors to cardiovascular morbidity and 
mortality.2 The treatment of the heart failure from myocardial infarction has slowly 
evolved over the past decades. A major turning point for restoring heart function was the 
scientific evidence that thrombus formation led to myocardial infarction and not vice 
versa.3-5 After myocardial infarction, the affected cardiomyocytes begin to die and are 
replaced with a collagenous scar within weeks. The adjacent myocardium continues to 
create tension on the scar region with every beat, causing the damaged ventricular wall 
to thin and dilate. With a larger ventricular volume but less functional myocardium, the 
heart can no longer maintain cardiac output and eventually leads to heart failure. This led 
to the, now common, practice of reperfusion therapy upon arriving to the hospital. 
Despite restored blood flow, the lack of sufficient regeneration to replace damaged tissue 
and the constant demand to pump blood to the entire body causes the heart to 
progressively fail.6  
Today the most common treatment is to reduce demand on the heart with 
therapeutic strategies (e.g, beta-blockers) or completely replace the heart with either a 
heart transplant (limited by donor supply) or with a left ventricular assist device (LVAD). 
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Despite prolonging life, this status quo for heart failure treatment remains limited by not 
achieving a restoration of heart function through regeneration of myocardium. Presently, 
the only long-term solution is cardiac transplantation, a procedure severely limited by the 
shortage of donor heart and by cost.7,8 Due to the limited regeneration capacity of adult 
human hearts, the human induced pluripotent stem cell (hiPSC) has emerged as a 
powerful cell source for cardiac repair due to its proven capacity to produce patient-
specific functional cardiomyocytes.9-13 In addition, recent progress in cardiac 
differentiation of hiPSCs allows for the derivation of the large amount of patient-specific 
human cardiomyocytes (~1x109 cells/patient), including from heart failure patients, 
needed for the idealized cardiac repair or large scale drug screening.14-18 Despite the 
progress in heart failure treatment in the last 50 years, notably less progress has been 
made in the last decade to advance the heart failure therapeutic paradigm.19,20 
Development of a biomimetic model to recapitulate the tissue-level dynamics of human 
ventricular cardiac tissues would provide a valuable tool to further investigate the 
physiology and pathology of human hearts and their diseases. 
 
Applications in Basic Research 
Although hiPSC-CMs provide a human cardiomyocyte model, the complexity of 
the multi-cellular nature and developmental stage of adult ventricular myocardium has 
led to significant challenges in modeling human cardiac tissue in vitro. The current 
cardiomyocytes derived from hESCs and hiPSCs retain an immature phenotype, including 
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poor contraction, metabolism, structure, and electrophysiology.21-24 During embryonic 
development, environmental factors (e.g., extracellular matrix- ECM, growth factors, 
mechanical and electrical stimulation) have major effects on the maturation of 
cardiomyocytes. To mimic the maturation process in vitro, hESC- and hiPSC-derived 
cardiomyocytes have been mixed with scaffolding materials (e.g., Matrigel and collagen 
type I gel) to prepare cardiac tissue-engineered constructs and then conditioned with 
electrical and/or mechanical stimulation.21,25-27 While these scaffolds can provide tissue-
like 3D microenvironments, current scaffolding materials lack the matched 
physical/chemical/biological properties with the native extracellular environments during 
heart development. On the other hand, scaffold-free, 3D cardiac spheroids have emerged 
as promising model systems to mimic cardiac tissues by providing a consistent, high 
throughput method to produce microtissue with biomimetic cell densities that rely on 
self-assembly mechanisms and endogenous scaffolding material production (i.e., 
ECM).28,29  
Various tissue-engineering strategies have been utilized to mimic adult host 
ventricular myocardium to accelerate phenotypic development of hiPSC-CMs.21,30-36 To 
this end, several groups have used electrical stimulation as an exogenous approach to 
recapitulate the natural pacemaker-initiated excitation of cardiomyocyte contraction to 
advance the function of hESC/hiPSC-CMs.21,35,37-42 Eng and others demonstrated that 
electrical conditioning of 3D cardiac embryoid bodies promotes cellular maturity of hiPSC-
CMs and affects intrinsic beating characteristics.39 Likewise, electrical nanomaterials have 
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provided an endogenous means of improving electrical conductivities of cardiac 
microtissues.43-45  
A combination of tissue-engineered strategies may be required to advance the 
functional assembly of hiPSC-CMs. In vitro methods, including mechanical and exogenous 
electrical stimulation, 3D microtissue culture, and capillary-like nutrient/drug delivery, 
have targeted physiologically relevant features that improved in vitro cardiomyocyte 
development.25,39,46-49 For example, Thavandiran and coworkers combined the aligned 
features of the myocardium with electrical stimulation to improve the functional 
development of cardiac microtissues.50 To mimic myocardial nutrient exchange, Mathur 
and coworkers showed that microfabricated channels surrounding CM constructs 
provided capillary-like diffusion that improved the physiological relevance of drug 
screening.46 To improve cell viability and integration after transplantation into infarcted 
hearts, Stevens and coworkers fabricated pre-vascularized cardiac patches that can 
connect to the host vasculature.51 In the most recent pursuit of ventricular cardiac tissue 
maturation, Ronaldson-Bouchard and others used a fibrin-based anisotropic hiPSC-CM 
microtissue model with 25% dermal fibroblasts to construct a microtissue that was 
electrically stimulated at increasing speeds that resulted in major hallmarks in mature 
ventricular cardiomyocytes including sarcomere M-line ultrastructures, ventricular-like 
electrophysiology and calcium handling, T-tubules, and oxidative phosphorylation shifts 
in metabolism.52 In this study, they provided evidence that earlier hiPSC-CM in vitro age 
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increased its in vitro maturation potential in a shorter time, suggesting hiPSC-CM 
development may involve several stages of lineage commitment.  
While previous approaches allow for focused study on hiPSC-CM function and 
maturation, there has been limited progress towards the development of an organotypic 
functional 3D cardiac model of the working myocardium. The heart is composed of more 
than simply cardiomyocytes and fibroblasts and independent studies have supported the 
benefit of additional cell types in improving overall tissue function, such as improved 
conduction velocity or vascularization.32,39,51,53-55 The human induced pluripotent stem 
cell (hiPSC)-enabled development of human organoids has provided a powerful platform 
for isogenic disease modeling and investigation of developmental biology that inherently 
contains a variety of cell types.56-58 To this end, a variety of functional tissue organoids 
(e.g., kidney, liver, brain) have been developed with the purpose of recapitulating major 
organ functions and structures, yet few studies have focused on the development of 
human cardiac organoids. A biomimetic approach for human organoid design may 
provide an accessible multi-dimensional in vitro model that can give further insight into 
tissue development without the need for more expensive, less human-specific animal 
models of heart tissue. 
 
Applications in Drug Discovery 
 Despite improvements in heart failure therapies in the past 50 years, it was only 
recently that the PARADIGM-HF trial proved to be the first in 30 years to show a new drug 
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outperforming treatment developed in the late 1980s.59,60 From 2003 to 2011, the 
likelihood of FDA approval of cardiovascular disease therapies from Phase I was 7%, which 
is below the average likelihood for all major disease categories (10%), and had the lowest 
success rate from Phase II (26%).61 In addition to clinical trial design, this has been, in part, 
attributed to translational discrepancies of preclinical data to outcomes in humans.62,63 
While many single pathways (e.g., B-AR biased ligands) and contributing cell types (e.g., 
epicardial cell) in heart failure have been thoroughly studied in single cell systems, the 
tissue-level response is only screened in the context of preclinical/clinical models. 
Although preclinical models provide a whole-organism context to evaluate novel 
therapies, tissue-specific characteristics and disease progression have notable differences 
across species, especially in smaller mammals (e.g. mouse).64-66  
Given the differences between species, recent progress in human induced 
pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) technology has aimed to 
incorporate hiPSC-CM 2D models to drug development/safety pipelines.67,68 Current 
standards for drug cardiotoxicity evaluation focus on detection of delayed ventricular 
repolarization, which is strongly associated with fatal ventricular arrhythmias, including 
torsades de pointes.69 hERG channel blockade and QT interval prolongation in 
electrocardiograms have been used as the industry standard targets for detection. The 
evaluation methods usually involve overexpressed non-cardiac cell types (e.g., hERG-
transfected CHO cells) and electrocardiogram assays in animal models (e.g. Langendorff-
perfused rabbit hearts).70-73 While these methods have successfully reduced drug 
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withdrawals, they also limited the pace and productivity of drug evaluation by eliminating 
potentially effective drugs that operate through alternative pathways (e.g., multi-channel 
effects).69,74 Developing novel high throughput drug cardiotoxicity screening systems 
using hiPSC-CMs with the improved clinical relevance would greatly accelerate the pace 
of therapeutic discovery as it can allow for robust derivation of patient-specific human 
cardiomyocytes (hiPSC-CMs).15,16,75-78 To this end, several reports have shown the 
feasibility of the utilization of the conventional 2D hiPSC-CM culture system for drug 
arrhythmogenic tests.79-84 In addition, tissue engineering strategies have been employed 
to assemble hiPSC-CMs into 3D cardiac (micro-)tissues to mimic structural features of 
myocardium (e.g., cell alignment, capillary-like media flow) to improve their physiological 
relevance, drug cardiotoxicity  predictability and reduce drug response variation.26,46,85,86 
However, the lack of control in the hiPSC-CM assembly process hinders the formation of 
proper cell-cell conjunctions and leads to the compromised cardiac functions (e.g., 
unsynchronized contraction). Further, the drug response data found in human adult 
ventricular tissue slices differs significantly from the existing hiPSC-CM systems. This has 
been, at least partially, attributed to the overall immature phenotype of the current 
hiPSC-CMs.87  
This highlights an unmet need to develop a biomimetic in vitro human model that 
incorporates tissue-level properties to provide a representative screening platform that 
shares functional and species similarities to humans prior to animal studies. This would 
reduce novel candidates earlier in the pipeline and thereby accelerate and improve 
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accuracy of heart failure drug development. Given the patient-specific nature of induced 
pluripotent stem cell (iPSC) technology, the majority of translational iPSC-based organoid 
work has focused on genetic disorders to treat with gene-targeted approaches (e.g., 
CRISPR-Cas9) or to serve as a patient-specific drug screening platform.88-92 In addition to 
heart failure, congenital heart disease occurs in ~1% of live births, ~10% of aborted 
fetuses, and is the leading cause of mortality from birth defects.93,94 Biomimetic cardiac 
model design can also contribute to this significant medical need by incorporating patient-
specific iPSC-cardiac models to address genetic mutation disorders.95-101 For example, 
Wang and others provided new insight into the pathogenesis of Barth syndrome that 
linked this mitochondrial cardiomyopathy with contractile dysfunction that was 
facilitated by a tissue-level hiPSC-CM model.102 
 
Applications in Cell Therapy 
 In addition to purely in vitro models, biomimetic human cardiac models also hold 
promise in the design of an advanced cell therapy vehicles to maximize their regenerative 
capacity. The field of cell therapy provides an injection-based strategy (i.e., intravenous, 
intracoronary, or intramyocardial delivery) to regenerate lost myocardium that avoids the 
highly invasive surgery needed for heart transplantation, LVAD insertion, and proposed 
tissue engineered patch strategies.103 Traditionally, adult stem cells (e.g., mesenchymal 
stem cells) have been a common source of exploration due to their multipotency and 
availability in adults. Additionally, advances in induced pluripotent stem cell (iPSC) 
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technology has furthered this potential with a patient-specific cell source, avoiding life 
time immunosuppressant therapy in the case of heart transplants and/or allogeneic 
cells.100,104 
The guiding principal for cardiac cell therapy has largely been focused on the 
pluripotency and proliferative capacity of the injected cells over other strategies, such as 
mimicking naturally occurring regenerative/survival mechanisms. The initial research 
evaluation of the efficacy of embryonic stem cells (ESCs) showed a trend of cell survival 
and modest improved cardiac function in the rat infarct model.105-108 However, in-depth 
analysis of ESC transplantation in the uninjured and injured heart has shown teratoma 
formation in allogeneic and syngeneic recipients and increased immunological 
response.109-111 These results indicate that 1) the heart may not provide sufficient signals 
for in situ differentiation of pluripotent stem cells, 2) an ESC-based method would require 
a level of immunosuppressant therapy, and 3) a more differentiated cell type may be 
necessary for successful integration and long term benefits. 
 Based on the ground work in pluripotent and multipotent stem cell 
transplantation in infarcted hearts, it can be reasoned that cells with a cardiac-committed 
lineage may have the most regenerative potential due to their ability to differentiate into 
cells important for cardiac repair, such as cardiomyocytes and endothelial cells.112 For the 
extent of this discussion, cardiac-committed cells will not be fully defined, but include 
cardiopoietic cell strategies (e.g., c-kit+ stem cells, cardiosphere-derived cells). To explore 
the therapeutic benefit of a cardiac-committed stem cell population, Menasche’s group 
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in 2005 conducted a preclinical study using cardiac-committed mouse ESCs in an infarcted 
sheep model that showed differentiation into cardiomyocytes and an increase in ejection 
fraction from 39% to 45.6% after 1, whereas media-inject controls decreased from 43% 
to 33.1%.113 Marban’s group then investigated the efficacy of cardiosphere-derived cells 
expanded from percutaneous endomyocardial biopsy specimens in a porcine model that 
showed an increase in ejection fraction from ~41% to 44% after 8 weeks while the PBS 
injected control changed from 42% to 36%.114 These studies helped to launch human 
cardiac-committed cells to human trials to make up the next generation of cell therapy 
strategies for heart failure.115 
 Most recently, the C-CURE trial investigated the efficacy of cardiopoietic stem cell 
derived from mesenchymal stem cells in chronic heart failure patients using an 
endoventricular guided catheter delivery of 600-1,200 x 106 cells that can 
electromechanically map viable and dysfunctional myocardium for precision-mapped 
injection.116 This cell therapy resulted in significant improvements in ejection fraction 
(from ~27% to ~34% in treated) with no improvements in standard-of-care controls. 
Overall, there seems to be improvements in function with cardiac-committed cell therapy 
in the short term analysis of these early stage approaches, but more trials on larger 
populations must be conducted to obtain a more accurate representation of treatment 
efficacies. Furthermore, the number of cells needed for current cell therapy strategies 
emphasize the need for improved methods for cell retention. 
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 Heart failure after myocardial infarction is caused in part by the inability of the 
sufficient force generation due to lack of healthy myocardium. With this aspect of the 
problem in sight and with improved protocols for cardiomyocyte differentiation, many 
groups have explored the use of stem cell-derived cardiomyocytes as the cell source for 
cardiac cell therapy. This method does not depend on in situ differentiation after 
transplantation and therefore theoretically could accelerate the regeneration of force-
generating myocardium. Initial studies using neonatal rat cardiomyocytes results 
validated the basis for the use of stem cell-derived cardiomyocytes, as they are also not 
fully matured cardiomyocytes.24,30 Initial studies of human embryonic stem cell-derived 
cardiomyocyte (hESC-CM) cell therapy confirmed their survivability and 
electromechanical integration of after transplantation into uninjured and 
electrophysiologically silenced.117-119 Based on the previous research in smaller animal 
models and the progression of stem cell-derived cardiomyocyte culture (both hESC-CMs 
and hiPSC-CMs), a large animal model was explored recently to evaluate the feasibility of 
mass production of stem cell-derived cardiomyocytes and efficacy of intramyocardial 
delivery in a non-human primate model (macaque, 100-150 BPM), of myocardial 
ischemia-reperfusion injury.120 This study involved injection of 1 x 109 hESC-CMs that 
showed substantial remuscularization (averaging 40% of infarct volume), perfusion by 
host vasculature, and graft-host electromechanical junctions that increased over 84 days 
after injection. Functional metrics (e.g., ejection fraction) among hearts receiving hESC-
CM showed no significant trends given the limited injured after ischemia-reperfusion 
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compared to an infarction model. However, it must be considered that sample sizes of 
this study were 1 at 14 days, 2 at 28 days, and 1 at 84 days, statistically limiting any 
conclusions on efficacy. In regards to the electrophysiology, all animals showed no 
arrhythmias prior to injection, but all developed arrhythmias after receiving hESC-CMs 
(i.e., premature ventricular contractions and periods of ventricular tachycardia). Most 
notably, this data contrasts with the previous work in small animal models and has led to 
increased discussion about stem cell-derived cardiomyocyte safety concerns.121 This also 
emphasizes the need to further understand the capacity of stem cell-derived 
cardiomyocytes, which may require improved in vitro models to increased understanding 
of hiPSC-CM maturation prior to injection or other strategies to promote favorable 
integration. 
 Given the diverse approaches for cardiac cell and biomaterial therapy with modest 
improvements, a multi-dimensional approach may be ideal solution. Many groups are 
exploring combining cell types and technologies to address each obstacle for successful 
retention and integration. Developmental mechanisms for vascularization of forming 
heart has inspired the use of epicardial-derived progenitor cells in conjunction with 
cardiac progenitor cells that has shown to be more angiogenic and resistant to hypoxia 
leading to improvements ejection fraction in mice.122 Multicellular aggregates with 
controlled assembly or hybrid cell types have been more frequent in efforts to take 
advantage of resistant cell types and pro-angiogenic features for improved integration.123-
126 With enhanced technology and techniques (e.g., RNA-seq, microarrays) to analyze 
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large amounts of data and combinations of data, the injection-based therapy approach 
to cardiac repair may not be only dependent on what cell type is best, but what 
combination of cells, materials, and factors has the strongest biomimetic rationale to 





UNDERSTANDING THE CELL MICROENVIRONMENT THROUGH BIOINK INK 




Three-dimensional (3D) bioprinting technology has provided an enhanced 
feasibility and precision for tissue engineered construct fabrication.127-135 Compared with 
the traditional tissue fabrication methods, 3D bioprinting offers a reproducible, scalable 
fabrication methodology with precise 3D control. It allows for the fabrication of 
mechanically supportive 3D structures with bioactive/cellular components for a variety of 
biomedical applications, including regenerative medicine, in vitro disease models, and the 
exploration of fundamental cell and tissue-level mechanisms.136-143 For tissue 
engineering, the ideal 3D-printed construct would be a growth-directing structure on 
which cells could migrate and proliferate to form a functional tissue. While genetics can 
control cell fate, the research in this field has proven to be tedious and rather complex.144 
In addition to the difficulty of using genetic tools to direct cell fate, epigenetics has shown 
that covalent and noncovalent modifications (e.g., DNA methylation), both to the DNA 
and histone protein organization in chromatin, act as a liaison between the inherited 
genotype and resulting phenotype.145,146 Without diving into the genetic and epigenetic 
world, the local environment of the cell, or microenvironment, is the natural grounds for 
influencing cell fate, as seen in developmental biology.147 It is the extracellular matrix 
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(ECM) of the cellular microenvironment that serves as a platform for mechanical and 
chemical cues, which can be created in vitro through 3D printing.  
To facilitate tissue formation, alginates have been extensively utilized as bioink to 
provide a matrix scaffold to direct a specific 3D cell growth because it can robustly form 
cell-compatible hydrogels in physiological conditions. In addition, it can be modified for a 
variety of tissue engineering applications, including bone, vascular, and adipose tissue 
engineering.127,148-157 However, native alginate is a bioinert material (i.e., lack of cell-
adhesive moieties) with limited biodegradation.135,150,153 Mooney and coworkers have 
shown that chemical modification of alginate through oxidation allows for controlled 
degradation.158-160 Due to this desirable characteristic for tissue engineering applications, 
oxidized alginate holds great potential as ink for bioprinting. However, little previous 
research has explored the applications of oxidized alginates in bioprinting.  
In this study, we prepared a library of 30 different alginate solutions with varied 
oxidation percentages and concentrations to develop a tunable bioink platform for 
bioprinting that can be modified for a wide range of tissue engineering applications. To 
this end, we have analyzed two key physical properties (i.e., viscosity and density) for the 
alginate solutions in the library and systematically investigated the effects of those 
physical properties of the alginates on their printability using a piston-driven, liquid-
dispensing system and human adipose-derived stem cells (hADSCs). hADSCs were 
selected in this study because of their high proliferation rates, a persistent multipotency, 
and a well characterized morphology in 2D culture.161 This has allowed for the 
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identification of a suitable range of material properties of alginates for bioink 
development. Further, the alginate-based bioinks were shown to be capable of 
modulating important stem cell behavior, such as proliferation and spreading, without 
affecting their printability and structural integrity after 8 days in cell culture (Fig. 1.1). The 
research reported here will accelerate the development of alginate-based bioink for 
tissue-specific tissue engineering applications.   
 
Results and Discussion 
Alginate has been widely used as a cell encapsulation material and in tissue 
engineering scaffolds.148,162 However, native alginate is a bio-inert material with limited 
Figure 1.1 Schematic representation of biodegradable oxidized alginate as bioink for 
bioprinting. A bioink consisting of RGD-modified oxidized alginate hADSCs was printed 
in a define lattice structure on a gelatin substrate to crosslink the hydrogel. The 
constructs were then evaluated over an 8-day period for cellular behavior (i.e., cell 
proliferation and spreading). 
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biodegradation. To improve this, Mooney’s group introduced a controllable degradation 
process using oxidized alginates reported in Bouhadir et al. 2001, which showed a 
promising capability as scaffold for tissue engineering applications.158,160,163 These 
biodegradable alginates thus have great potential to develop a bioink platform for 3D 
bioprinting.  
In 3D printing, there are multiple, unique dispensing systems to achieve high 
resolution, and each system has specific requirements for the optimal ink.164 Among the 
various liquid-dispensing systems, piston-driven deposition has recently received 
significant attention because it offers a significantly high fabrication speed and is capable 
of fabricating anatomically shaped, clinically relevant-sized constructs.165,166 They require 
a bioink with a suitable density and viscosity as well as the capability to retain printing 
fidelity and high cell viability post-printing.167 In this study, we used a custom-made, 
piston-driven deposition system, as a test bed to examine the printability of 
biodegradable alginates. The printability here is defined as having high printing resolution 
and fidelity, a homogeneous cell distribution, and high cell viability post-printing. In 
addition, a lattice structure was utilized as our standard to evaluate printing resolution 
and fidelity in this study because it has been shown to promote cell viability and cell 
function (i.e. proliferation), offering the possibility of long-term culture in vitro without 
the assistance of a bioreactor.168 
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Initial efforts focused on the oxidized alginate previously utilized for tissue 
engineering applications, such as 5% ox.-2% conc. (i.e., alginate with 5% oxidation and 2% 
(w/w) concentration).158 However, these alginate solutions did not provide sufficient 
printing resolution for a lattice structure due to its low viscosity (Fig. 1.3b, top). Also, 
alternating the oxidization percentage between 0% (non-degradable), 1%, 3%, 5%, and 
10% proved to be inadequate to increase resolution for a 2% concentration solution. 
Meanwhile, other reported attempts to increase resolution while maintaining high cell 
viability in literature have used higher concentrations.168 Therefore, a range of 
concentrations (2%, 5%, 8%, 10%, 15%, and 20%) mixed with different oxidation levels 
was designed to create a library composed of 30 different alginates (Fig. 1.2). Using the 
three criteria for printability evaluation (i.e., homogenous cell distribution, high printing 
Figure 1.2. Density-based analysis on printability of different alginate solutions. (a) 
Density (mean ± SD) measurements of each sample with successful cell suspension 
results (green). Red denotes alginate compositions that did not completely dissolve 
into solution after 2 days. The other materials (white) were unable to maintain a 
homogenous cell distribution. (b) Calcein-stained hADSCs in the 5% ox.-10% conc. 
(left) and 5% ox.-2% conc. (right) material with and without successful cell suspension, 
respectively (scale bar= 500 µm).  
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resolution, and high cell viability post-printing)168-170, we systematically examined the 
material properties and printability of these alginates with hADSCs as a model cell line 
using a piston-driven, liquid-dispensing system.  
Density and cell suspension tests of different alginate solutions. Homogeneity of 
cell distribution after printing is critical for the ideal bioink. To achieve a homogeneous 
cell suspension throughout the whole printing process, the density of the biomaterial 
should be close to or above that of the examined cell type.171 By altering oxidation and 
concentration, a matrix of alginate densities was made (Fig. 1.2a). With increasing 
concentration and decreasing degree of oxidation, the densities of alginates showed an 
increasing trend. Given a printing operation time of 3 hours, we identified the range of 
materials that keep cells homogenously distributed for printing with a piston-driven 
deposition system (Fig. 1.2a, green), which was verified by fluorescently labeled cell 
suspension tests (Fig. 1.2b). The results of this experiment and density measurements of 
all 30 materials confirm that a density around 1.05 g/cm3 can maintain a homogeneous 
cell suspension for hADSCs. This is in agreement with the study by Lin and others that 
optimized a polyethylene glycol (PEG)-based hydrogel with 37.5% Percoll to attain the 
needed density to suspend hADSCs.171 Density, thus, can define a limit for bioprinting 
alginate solutions. The individual cell density and biomaterial density must be taken into 
account when applying a density-based selection to other systems. It is important to note 
that a wider range of densities around 1.05 g/cm3 can maintain a hADSC suspension within 
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a 3 hour printing process time without significant cell movement, due to the relatively 
high viscosity that slows the process of cell movement.  
Viscosities of 30 different alginate solutions. Given that viscosity plays an 
important role in a liquid-dispensing printer164, its effects on printability (i.e., printing 
resolution) were examined to determine a viscosity-based range for oxidized alginate ink. 
We found that altering oxidation and concentration resulted in a practical method of 
controlling the viscosity of degradable alginates. A similar pattern to the density 
measurements was observed: as the concentration increased or the degree of oxidation 
decreased, the viscosity showed an increasing trend (Fig. 1.3a). In addition, we have 
Figure 1.3. Viscosity-based analysis on printability of different alginate solutions. (a) 
Viscosity values of various alginate solutions with a range of concentrations and 
oxidation levels that passed the density requirement shown with a favorable area for 
higher resolution bioprinting with hADSCs (green). Red denotes alginate compositions 
that did not completely dissolved into solution after 2 days. The other materials were 
either too viscous to prepare for printing or failed the density test (white). (b) Using 
dots as the functional unit of liquid-dispensing strategies and a representation of 
resolution, a printed dot array (5×5) shows examples of low printing resolution (top), 
high printing resolution (low) (scale bar= 1 mm). (c) A plot of areas of dots versus 
viscosity shows a direct relationship between printability and viscosity of alginate 
samples. Guiding lines represent general flow of data. 
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printed 5×5 arrays of dots using different biodegradable alginates to examine the effect 
of viscosity on dot fidelity and size, which determines printing resolution. As shown in 
Figure 1.3b and Figure 1.3c, there is an optimal range of viscosity (i.e., ~200 mm2/s to 
~3000 mm2/s) for the improved printing resolution independent of concentration and 
oxidation degree of alginate solution. This indicates the critical role of viscosity in printing 
resolution for a piston-driven, liquid-dispensing system. At the low viscosity end (i.e., 
<200 mm2/s), low concentration alginates produced larger dots when compared with 
alginates within the optimal range of viscosities (Fig. 1.3c). On the other hand, an upper 
threshold (i.e., >3000 mm2/s) also exists due to the increased liquid handling difficulty 
after a certain viscosity value (Fig. 1.3c). It is known that high viscosity can alter liquid-
dispensing characteristics of the solution. For example, Schuurman and coworkers 
reported that high viscosity materials can form filaments rather than droplets when 
depositing.172 Notably, alginate solutions with viscosities between ~200 mm2/s and ~400 
mm2/s typically had densities lower than the threshold necessary for maintaining 
homogenous cell suspension (i.e., <1.05g/mL). The viscosity range suitable for high 
printability was therefore refined to ~400 mm2/s to ~3000 mm2/s. The alginate solutions 
within the optimal range of viscosity are highlighted in green in Figure 1.3a. The data 
presented in Figure 1.3a will enhance the available viscosity data on alginates used in 
other bioink development research with liquid-dispensing systems.173-175 
hADSC viability in the printed alginate. Cell viability, as one of the standards of 
biocompatibility for bioink, was analyzed after printing.170 To examine the effect of 
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printing on cells, viabilities were assayed immediately following the printing process (Figs. 
1.4a and 1.4b). A compromised cell viability (<90%) was found in the high viscosity 
alginates (>3000 mm2/s), while high cell viability (>90%) was found in the alginate 
solutions with the optimal/medium viscosity (~400 mm2/s to ~3000 mm2/s). The 
decreased cell viability in the high viscosity alginate samples was attributed to the limited 
Figure 1.4. Cell viability assay of density and viscosity criterion-filtered samples. (a) 
Samples of high viability (>90%) right after printing (green). (b) The fluorescent 
pictures of live-dead assay after printing: (i) high cell viability sample (e.g. 5% ox.-15% 
conc.) and (ii) low cell viability sample (e.g. 5% ox.-20% conc.) (scale bar= 100 µm). (c) 
Cell viability assay at day 8. Except the 5% ox.-20% conc. sample (0% viability), the 
remaining four samples showed high viabilities (>95%) after 8 days in culture (scale 
bar= 100 µm). 
 23 
nutrient transport (i.e., diffusivity). Viability assays were performed again after 8 days in 
cell culture, as shown in Figure 1.4c. The alginates with optimal/medium viscosity (i.e., 
~400 mm2/s to ~3000 mm2/s) again exhibited high viability (>90%), whereas the alginates 
with high viscosity showed a negligible viability (0%). The results indicate that alginates 
with high viscosity, although printable, may create an environment with poor nutrient 
transport, resulting in compromised cell viability, in accordance with previous 
studies.176,177 Given the importance of maintaining high cell viability post-printing, it is a 
key parameter to include when defining the range of engineered alginates for bioink. 
Summary of the oxidized alginates based on three printability criteria. The 
capacity to maintain homogenous cell suspension (influenced by the densities of alginates 
samples) and achieving high printing resolution and viability (both influenced by the 
viscosities of samples) are the three criteria for our bioink selection. Based on these 
criteria, a new table was assembled to highlight the printable alginate solutions (Fig. 1.5). 
It is important to note that these highlighted alginates can serve as base materials to 
Figure 1.5. Summary table of the preferable range of alginate samples with high 
printability (green) based on the three established printability criteria (i.e., 
homogeneous cell suspension, high printing resolution, and high cell viability). 
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develop bioinks with desired physical/chemical/biological properties for tissue-specific 
tissue engineering applications.160 Further, the density, viscosity, and viability analysis 
allowed for the identification of a suitable range of material properties of alginate 
solutions to be applied to bioprinting. This can provide a guideline for developing next 
generation of alginate-based bioink for 3D bioprinting-facilitated tissue engineering. 
Notably, Mooney and coworkers have demonstrated the independent control of elastic 
moduli and degradation rates of alginate hydrogels by creating binary alginate 
hydrogels.178    
Printing lattice-structured, cell-laden alginate hydrogels and cell culture. Lattice 
structures have been shown to support higher cell viability and proliferation rate because 
they offer a conducive environment for nutrient supply and waste excretion.168 In this 
study, we designed a point-to-point protocol to produce cell-laden hydrogels with a 
lattice structure of 7 columns and 7 rows.  They have optimal expected dimensions of 
12.6 mm x 12.6 mm (X, Y) based on a printing design dimension of 12 mm × 12 mm (from 
the center of dot placement) and a Z dimension limited to one layer (Fig. 1.6a). To 
examine the effects of the biodegradability of oxidized alginate, we selected samples with 
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low degradable (0% ox.), medium degradable (5% ox.), and high degradable (10% ox.) 
characteristics. The density, viscosity, and viability analysis allow for the selection of the 
appropriate concentrations for each alginate sample (0% ox.-8% conc., 5% ox. -10% conc., 
5% ox.-15% conc., 10% ox.-15% conc.) to be printed with suspended hADSCs. Although 
these four materials have significant differences in their physical properties (i.e., density 
and viscosity) (Figs. 1.2 and 1.3), they all can be successfully printed into lattice-
structured, cell-laden hydrogels with homogeneous cell distribution (Figs. 1.6 and 1.7a). 
Figure 1.6. Lattice structures printed with bioprinting-compatible materials and their 
dimensional change in 8 days. (a) Initial design of lattice structure. (b) Pictures of 
printed lattice structures (5% ox.-10% conc. sample) at day 0, day 4, day 8 shows 
printed structures highly matched the initial design with apparent dimensional 
changes after 8 days in culture (scale bar= 2 mm). (c) Normalized comparison between 
the initial design (12.6 mm x 12.6 mm) and the X and Y dimensions of the lattice 
structures (0% ox.-8% conc., 5% ox.-10% conc., 5% ox.-15% conc. ) after 8 days in 
culture. All values are mean ± SD. Asterisk denotes significant difference between day 
0 and day 8. 
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Notably, the dimensions of all the printed lattice structures were within 10% of the 
optimal expected dimensions (i.e., 12.6 mm x 12.6 mm) (Fig. 1.6c), which can be defined 
as accurately printed structures.179 
All lattice structures were cultured for 8 days. For the samples that maintained 
measurable structures, the changes in length and width were measured at day 0, day 4, 
and day 8, and the extent of dimensional changes were determined (Fig. 1.6c). The 0% 
ox.-8% conc., 5% ox.-10% conc., and 5% ox.-15% conc. samples remained intact through 
8 days in culture, and the rapid degradation of 10% ox.-15% conc. alginate resulted in 
almost complete fracture of the structure by day 8.158 Further, no significant change in 
dimension (Y dimension, p=0.10; X dimension, p=0.27) was observed in the 0% ox.-8% 
conc. sample from day 0 to day 8 (Fig. 1.6c), whereas a significant dimensional decrease 
(Y dimension, p<0.05; X dimension, p<0.05) was observed in the 5% ox.-10% conc. and 
the 5% ox.-15% conc. samples from day 0 to day 8. The decrease in dimension of the 
oxidized alginate samples was attributed to their biodegradation and cell activities. This 
consistent decrease should be considered, especially for dimension-specific designs when 
using dynamic or prolonged culture methods. 
hADSC spreading and proliferation assays in printed lattice structures. In 
addition to maintaining cell viability, a bioink platform should allow for the modulation of 
cell behaviors. In this study, proliferation and spreading of hADSCs were examined due to 
their important roles in tissue engineering applications. In particular, cell spreading can 
be used to modulate self-renewal and differentiation of hADSCs.180-182 Cell-adhesive RGD 
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peptide, a widely known cell attachment promoter molecule150,183-185, was conjugated to 
alginate bioink in this study to promote cell proliferation and spreading (Fig. 1.9). DAPI 
staining for nuclei and phalloidin staining for actin were used to characterize the cell 
behavior in each structure (Fig. 1.7a). As shown in Figure 1.7a, 1.7b, and 1.7c, the oxidized 
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alginate bioinks (i.e., 5% ox.-10% conc., 5% ox.-15% conc., and 10% ox.-15% conc. 
samples) can effectively promote cell proliferation and spreading when compared to the 
non-oxidized alginate bioink (i.e., 0% ox.-8% conc. alginate). Quantitatively, the cell 
proliferation percentages after 8 days in culture were 173% for the 0% ox.-8% conc. 
alginate, 232% for the 5% ox.-10% conc. alginate, 248% for the 5% ox.-15% conc. alginate 
(Fig. 1.7b), and 190% for the 10% ox.-15% conc. alginate at day 4. For cell spreading, the 
average cell size did not change significantly after 8 days in culture for the 0% ox.-8% conc. 
alginate, while cell size increased 25% for the 5% ox.-10% conc. alginate, 161% for the 5% 
ox.-15% conc. alginate at day 8, and 69% for the 10% ox.-15% conc. alginate at day 4 (Fig. 
1.7c). The low cell proliferation and cell spreading in the 0% ox.-8% conc. alginate 
assumed to be attributed to its persistent low porosity given its limited degradability. In 
contrast, the significant increase in cell proliferation and spreading in the 5% ox.-15% 
conc. alginate was assumed to be attributed to the increasing porosity associated with its 
degradation. The vast difference in cell spreading among alginate bioinks with varied 
oxidation degree and concentration (i.e., 0% ox.-8% conc., 5% ox.-10% conc., and 5% ox.-
15% conc. samples) demonstrates their great potential in printing scaffolds tailored for 
specific tissue engineering applications. For example, the 0% ox.-8% conc. alginate 
Figure 1.7 (previous page). hADSC behavior in the lattice structures. (a) Cell spreading 
with fluorescent staining (phalloidin) for actin at day 0, 4, and 8 (scale bar= 100 µm). 
(b) hADSC proliferation index and spreading assays based on fluorescent staining 
(phalloidin and DAPI stain) at day 8. Proliferation index was calculated as the cell 
number of each day divided by the original cell number on day 0 for the 0% ox.-8% 
conc. alginate sample for relative comparison. Cell area was calculated as total cell 
area divided by the number of cells normalized over the values at day 0 for the 0% 
ox.-8% conc. alginate sample. All values are mean ± SD. 
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induced a round cell morphology that can be applied to chondrogenesis, while the 5% ox.-
15% conc. alginate was associated with an increased spreading phenotype that could 
facilitate osteogenesis.186-191 In addition, the cell-matrix-interactions between hADSCs 
and alginates were investigated using αvβ3 integrin immunofluorescent staining as shown 
in Figure 1.10. The RGD conjugation was found to promote integrin expression at all three 
dates (i.e., day 0, day 4 and day 8). Interestingly, the αvβ3 integrin expression was found 
on day 8 for alginate samples without RGD conjugation, which was attributed to the ECM 
secreted by hADSCs, consistent with previous research.192 
Figure 1.8 is a 3D picture showing a portion of a lattice structure from the 5% ox.-
15% conc. oxidized alginate with hADSCs after 8 days in culture. The distribution of the 
observed spreading cells confirmed that the homogenous cell distribution in the alginate-
based bioink pre-printing was maintained in the lattice structure after 8 days in cell 
culture. Summarizing the results shown in Figure 1.6 and Figure 1.7, the alginate-based 
bioinks are capable of modulating hADSC proliferation and spreading without affecting 
Figure 1.8. A computer-rendered 3D picture of a portion of the printed lattice 
structure made by the best supporting hADSC material, 5% ox.-15% conc. oxidized 
alginate, showing multiple layers of spreading cells within the hydrogel. 
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structural integrity after 8 days in culture, apart from the highly degradable alginate 
sample, 10% ox.-15% conc.  This creates a solid foundation for the development of 
alginate-based bioink for 3D bioprinting-tailored tissue engineering scaffolds. 
 
Conclusion 
The primary characteristics influencing the printability of oxidized alginate as ink 
for bioprinting was defined by its ability to hold a homogeneous cell suspension, have 
high printing resolution, and support high cell viability. According to these factors, an ideal 
printable range for using oxidized alginate as a bioink platform was established. Further, 
by mimicking the adhesive cues (i.e., RGD) present in ECM, these alginate-based bioinks 
were shown to be capable of modulating hADSC functions without affecting their 
printability and structure integrity after cell culture. The introduction of oxidized alginate 
to bioprinting has led to the creation of a tunable bioink platform for a range of tissue 
fabrications. Based on our findings, the observed functional relationship between the 
material properties (i.e., viscosity and density) of alginate and its printability allows for an 
enhanced progression in alginate bioink development for liquid-dispensing printing. 
When using other cell types, metabolic demands may require an altered density and 
viscosity of oxidized alginate to allow for optimal diffusion of nutrients. Apart from 
diffusion limitations, the Ca2+ concentration used in the gelation process may also affect 
Ca2+-sensitive cell types, such as chondrocytes.193 This Ca2+ concentration can be adjusted 
to achieve higher viability, though a prolonged gelation time may affect the printing 
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fidelity and total printing time.194 Future studies in bioprinting technology and a widened 
understanding of self-assembly mechanisms between cells may reshape the demands for 
ink printability. 
 
Materials and Methods 
Materials. Sodium alginate was purchased from FMC BioPolymer (Philadelphia, 
PA). Ethylene glycol was purchased from Mallinckrodt Baker, Inc. (Phillipsburg, NJ). All 
other chemicals used for this study were purchased from Sigma-Aldrich (St. Louis, MO) 
unless otherwise stated. 
Alginate synthesis and oxidation. Sodium alginate was prepared using the method 
established by Bouhadir and others.158 Briefly, 1 g sodium alginate was dissolved in 100 
mL of distilled water. Sodium periodate was used as the oxidizing reagent and was added 
at room temperature in varying quantities, based on the desired percent oxidation (at 
oxidation percentage of 1%, 3%, 5%, 10%, w/w). The reaction was terminated by the 
addition of ethylene glycol after 24 hours. Sodium chloride (3 g) was then dissolved in the 
solution. Excess amount of ethyl alcohol was added to the solution (2:1 ratio), 
precipitating the oxidized alginates. The solution was centrifuged to collect the 
precipitates, and the ethanol wash was repeated. The oxidized alginate pellets were then 
lyophilized and stored at -20°C. 
RGD-alginate conjugation. To promote cell attachment and spreading, RGD 
peptides have been conjugated into oxidized alginates using a similar method as 
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Mooney’s group, reported in Rowley et al. 1999: utilizing aqueous carbodiimide chemistry 
with G4RGDSP-OH (International Peptides, Louisville, KY).150 The final modification 
percentage of RGD to alginate was 1% (w/w). 
Identification of viscosity and density. Aqueous alginate solutions (at oxidation 
percentage of 0%, 1%, 3%, 5%, 10% w/w) of varying concentration (2%, 5%, 8%, 10%, 15%, 
20% w/w) were made using a weight to total-weight ratio. To test viscosity, approximately 
8 mL of varying alginate solutions were made and tested three times by Cannon-Fenske 
Opaque Calibrated viscometers (Cannon® Instrument Company, Inc, USA) at 40 °C. 
Viscosity values were calculated according to Poiseuille’s law associated with the 
calibrated viscometers and then converted to kinematic viscosities by dividing by density. 
The density of the alginate solutions were calculated by measuring the mass of 1 mL of 
alginate aqueous solution three times and then averaged. 
Preparation of Ca2+-containing gelatin substrate for 3D-printing alginate 
hydrogels. To avoid reduced viability with high Ca2+ concentration solutions, a calcium 
substrate was prepared for alginate, as done previously.194 Briefly, a 100 mM CaCl2 gelatin 
solution was prepared by combining calcium chloride dehydrate, sodium chloride (0.9 
wt%), and porcine gelatin (2 wt%) in distilled water and boiled for 2 minutes. Aliquots of 
5 mL of gelatin were put into standard petri dishes to gel in a refrigerator overnight. 
Titanium dioxide (0.3% wt%) was added to the same solution and stirred for 10 min to 
increase the opacity of the resulting surface. 3 mL of the gelatin/TiO2 mixture was spread 
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evenly across the surface of the previously prepared gelatin plates and put in the 
refrigerator overnight to be used within 3 days. 
Printing process of alginate hydrogels. Aqueous alginate samples were prepared 
according to a weight to total-weight ratio using either distilled water (for density and 
viscosity tests) or cell medium (for dot analysis and cell studies) using the same 
preparation protocol. The bioink (with cells for cell study) were then loaded into a printer-
compatible syringe. All printing was performed on the Palmetto Printer, a custom-made, 
piston-driven deposition system, on a temperature-controlled plate at 4 °C. Droplet 
volume was maintained at 230 nL with a dispensing speed of 10 µL/sec. 
For dot analysis, a 5×5 dot array was printed for each sample and left to gel for 40 
min before macroscopic imaging with the Olympus SZX16 stereomicroscope. 
For lattice structure fabrication, single layer, cell-laden, lattice structures were 
printed with 7 columns and 7 rows using a point-to-point strategy to print every other dot 
with optimal expected dimensions of 12.6 mm x 12.6 mm (X, Y), which is a result of a 
printing design with dimensions of 12 mm × 12 mm (from the center of dot placement) 
(Fig. 1.3a). In liquid-dispensing printing, the point-to-point method allows for accurate 
control of design-specific structures. The bioink used for the structures were alginate 
solutions of 0% ox.-8% conc., 5% ox.-10% conc., 5% ox.-15% conc., 5% ox.-20% conc., 10% 
ox.-15% conc. Following printing, 8 mL of media was added to the gelatin plate and put in 
the incubator for approximately 30 min, melting the Ca2+-containing gelatin to maximize 
alginate crosslinking. Lattice structures were then transferred to individual wells in a 6-
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well plate for extended culture. Macroscopic pictures were taken with the Olympus SZX16 
stereomicroscope, and media was changed every 4 days for 8 days. 
Cell culture and cell behavior studies. Human adipose-derived stem cells (hADSC) 
(Lonza, Basel, Switzerland) were used to investigate the effects of the alginate gel’s 
oxidation and concentration on cell viability, attachment, and proliferation. The cells were 
cultured in low glucose DMEM with 10% FBS and 1% penicillin-streptomycin, 1% 
glutamine, and 1% antimycin (Gibco Life Technologies, Grand Island, NY). At >80% 
confluency, cells were detached using trypLE Express (Gibco Life Technologies) and 
passaged. All experiments were conducted using passage 5 (P5) hADSCs. Aqueous 
alginate solutions of varying oxidation and concentration were prepared using the cell 
culture medium and mixed with detached cells at a concentration of 1.3 million cells per 
mL. The samples were loaded into printer syringes, transported to the printer, and then 
printed as described in the previous section. 
hADSC suspension tests were performed by mixing aqueous alginate samples 
(made with media) of varying concentrations with live cells (1 mL of 1.3 million cells per 
mL) labeled with Calcein, AM (Gibco Life Technologies). The samples were loaded into 
NMR tubes and were left stationary for 3 hours. Then, each solution was partitioned from 
top to bottom into 5 parts, and the number of cells in each part was counted 
microscopically and analyzed. The macroscopic images were taken with the Olympus 
SZX16 stereomicroscope. 
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The cell-seeded hydrogels were assessed for cell viability post-printing using the 
live/dead cell viability assay kit from Invitrogen Life Technologies (Grand Island, NY) 
following the protocol of the kit. The cell viability percentage was calculated as the 
number of live cells (green-stained) over the total number of cells (green and red). 
Viability assays were performed for the printed structures again after 8 days of culture 
using portions of each structure. High viscosity samples of each oxidation (0% ox.-10% 
conc., 1% ox.-10% conc., 3% ox.-15% conc., 10% ox.-20% conc.) were later tested using 
the same post-printing method. All the fluorescent pictures were taken by Leica TCS SP5 
AOBS Confocal Microscope System. 
The lattice structures of five samples (0% ox.-8% conc., 5% ox.-10% conc., 5% ox.-
15% conc., 5% ox.-20% conc., 10% ox.-15% conc.) were printed with hADSCs following the 
protocol above. Cell proliferation and morphology for these samples were assessed at day 
0, day 4, and day 8 using portions of each structure with a fluorescent DAPI and phalloidin 
staining kit from Invitrogen Life Technologies (Grand Island, NY) by following the kit 
protocol. For cell proliferation analysis, the following cell counting method was utilized 
on each of the given days. At least 3 different pictures (600 µm x 600 µm, z-layer thickness 
≈ 100 µm) were taken of the respective hydrogel samples, and the cell number in 3 
random areas (200 µm x 200 µm, >10 cells/area) of each picture were manually counted 
based on DAPI and phalloidin staining. Proliferation index was calculated as the cell 
number of each day of each sample divided by the original cell number on day 0 for the 
0% ox.-8% conc. alginate sample. For cell morphology, fluorescent images of each sample 
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(at least 4 random pictures per sample, 600 µm x 600 µm per picture) were taken by the 
Leica TCS SP5 AOBS Confocal Microscope System using Z-stack parameters of 30 optical 
slices over a 300 µm depth. Cell sizes were measured through ImageJ threshold-based 
edge detection tools as a total cell area divided by the number of cells normalized over 
the values at day 0 for the 0% ox.-8% conc. alginate sample (Fig. 1.4c). The cell-matrix 
interactions between hADSCs and alginates were studied using mouse primary antibody 
for αvβ3 integrin (Abcam, Cambridge, MA) and rat (anti-mouse) secondary antibody, Alexa 
Fluor 546 (Invitrogen, Carlsbad, CA), both at 1:200 ratio. 
Rebuilt 3D image for printed lattice structure. The cells in the printed lattice 
structure were stained with fluorescently labeled phalloidin and imagined by Leica TCS 
SP5 AOBS Confocal Microscope System. These images were rebuilt into a 3D rendering 
using Amira software. 
Statistical analysis. The results were expressed as the mean ± standard deviation 
(SD) and analyzed using JMP 11 and Excel statistical software. Lattice dimensions were 
compared between day 0, day 4, and day 8 by a Student’s t-test. Dot analysis, viscosities, 
and densities were analyzed separately using unpaired Student’s t-tests. A confidence 






Figure 1.9. A proof-of-concept analysis of the necessity of 1% (w/w) RGD peptide-
conjugated alginate for changing cell function. In 5% ox.-10% conc. alginate hydrogel, 




Figure 1.10. αvβ3 integrin expression of hADSCs in alginate hydrogels with and without 
RGD conjugation at day 0, day 4, and day 8. Samples include 0% ox.-8% conc. without RGD 
conjugation, 0% ox.-8% conc. with RGD conjugation, and 5% ox.-15% conc. with RGD 
conjugation oxidized alginates. Blue – DAPI nuclear stain; Green – αvβ3 integrin (scale 




Table 1.1.  














Day 0 96% 98% 98% 19% 96% 
Day 4 93% 92% 96% 3% 92% 









 While biomaterials can provide molecular/mechanical signals to promote cell 
adhesion, proliferation, and enhance extracellular matrix (i.e., ECM) protein deposition 
and tissue formation195,196, scaffold-based approach faces numerous challenges. Apart 
from potential biocompatibility issues, one of the key challenges of using engineered 
biomaterials (e.g., functionalized alginate) is that identification of the ideal material 
depends on a sufficient understanding of the role of targeted processes in directing cell 
behavior.197 In the context of cardiac embryonic development, environmental factors 
(e.g., extracellular matrix, growth factors, mechanical and electrical stimulation) have 
major effects on the maturation of cardiomyocytes. To mimic the maturation process in 
vitro, stem cell-derived cardiomyocytes have been mixed with scaffolding materials (e.g., 
Matrigel and collagen type I gel) to prepare cardiac tissue-engineered constructs and then 
conditioned with electrical and/or mechanical stimulation.21,25-27 While these scaffolds 
can provide tissue-like 3D microenvironments, current scaffolding materials lack the 
matched physical/chemical/biological properties with the native extracellular 
environments during heart development. On the other hand, scaffold-free, 3D cardiac 
spherical microtissues (i.e., spheroids) have emerged as promising model systems to 
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mimic cardiac tissues by leveraging the ability of cells to self-assemble into microtissues 
at a high cell density with endogenous ECM production.28,29  
As physiological cardiac microtissue maturation depends on synchronized 
contractile activity, we previously developed a method to incorporate a trace amount of 
electrically conductive silicon nanowires (e-SiNWs) into otherwise scaffold-free, human 
induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) spheroids that 
significantly advanced the structural and contractile maturation of the cardiomyocytes 
across a range of viable sizes.45,198 This approach has a distinct advantage of only using a 
minimal amount of e-SiNWs (0.004% w/v), minimizing the adverse effects of traditional 
scaffolds, such as the unmatched physical/chemical/biological properties with the native 
extracellular environments during heart development. e-SiNWs were selected because of 
their controllable electrical conductivity, tunable dimensions, and convenient surface 
tailorability.199,200 In this study, n-type SiNWs (Diameter ≈ 100 nm; length ≈ 10 m; 
Silane/Phosphane = 500) were prepared according to the previously established 
protocol201 to obtain a high conductivity (150 - 500 S/m) and to avoid cell 
internalization.44,202 Although SiNWs might not be well known as biocompatible materials, 
in vitro biocompatibility studies have shown no significant cytotoxic effects for both 
undoped and n-type SiNWs203,204. Further, the recent research showed SiNWs are 
biodegradable, and their degradation products are found mainly in the form of Si(OH)4 
and are metabolically tolerant in vivo205-209.  This makes them advantageous over other 
non-biodegradable, electrically conductive nanomaterials (e.g., gold nanowires, carbon 
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nanotubes and nanofibers), especially for potential in vivo applications. We reasoned that 
the incorporation of e-SiNWs in cardiac spheroids facilitated the formation of an 
electrically conductive network, and provided synchronized and improved 
electrical/mechanical signals to advance structural and contractile maturation of the 
cardiomyocytes. 
While nanowired spheroid culture of hiPSC-CM significantly improved the 
contractile development, extended culture did not further improve cardiac maturation.45 
Enhanced maturation of hiPSC-CMs in vitro is a critical barrier for understanding the 
translational potential of patient-specific hiPSC-CMs for drug screening and/or cell 
therapy strategies to repair the damaged heart. To derive hiPSC-CMs suitable for cell 
transplantation, various tissue-engineering strategies have been utilized to mimic adult 
host ventricular myocardium to accelerate phenotypic development of hiPSC-CMs.21,30-36 
Particularly, several groups have used electrical stimulation as an exogenous approach to 
recapitulate the natural pacemaker-initiated excitation of cardiomyocyte contraction to 
advance the function of hESC/hiPSC-CMs.21,35,37-42  
We reasoned that exogenous electrical stimulation could synergize with the 
endogenous benefits of nanowired spheroids to improve the functional development of 
hiPSC-CMs in cardiac spheroids. To this end, we developed a viable strategy to electrically 
stimulate nanowired hiPSC cardiac spheroids and examined the effects of electrical 
stimulation and silicon nanowires on the functions of spheroids. Herein, for the first time, 
we show that the synergy of exogenous electrical stimulation and nanowires to hiPSC 
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cardiac spheroids 1) enhanced microtissue development through formation of functional 
cell-cell junctions, 2) improved development of contractile properties of hiPSC-CMs, and 
3) decreased the endogenous spontaneous beat rate for reduced arrhythmogenic 
potential. Through tissue- and cell-level examination of cardiac spheroids, the progress 
here contributes to the fundamental understanding of hiPSC cardiac microtissue 
development and addresses the need for an advanced, functional cardiac cell therapy 
vehicle for future cardiac tissue repair. 
 
Results and Discussion 
 Development of electrically stimulated, nanowired hiPSC-CM spheroids. In the 
adult heart, ventricular cardiomyocytes contract regularly due to the depolarizing 
electrical propagation originating in the sino-atrial node of the heart. To mimic this 
stimulation for contraction, cardiac tissue engineering strategies have utilized electrical 
pacing to develop and maintain cardiomyocyte function.35,38,39,41,210-212 During our 
previous development of nanowired cardiac spheroids, electrical stimulation (3.75 V/cm, 
1 Hz, 2 ms) successfully maintained contractile function when applied to scaffold-free 
spheroids composed of enriched neonatal rat cardiomyocytes (i.e., <25% fibroblasts).45 
Based on electrical stimulation protocols for human cardiac tissue constructs established 
in previous studies and a spheroid size within the diffusional limit (i.e., 150 µm radius), 
we empirically developed a viable electrical stimulation protocol (2.5 V/cm, 1 Hz, 5 ms) 
that supports optimal hiPSC cardiac spheroid viability and function (Figure 2.1, 2.6).40,41 
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Compared to unstimulated and unwired spheroids at Day 0 (NC-D0), treatment groups 
consisted of spheroids in prolonged culture (Day 19 - D19): unstimulated and unwired 
Figure 2.1. Development of electrical stimulation for nanowired hiPSC cardiac 
spheroids. (A) The schematic diagram of the stimulation setup shows cardiac spheroids 
cultured in non-adhesive agarose molds between carbon electrodes. (B) Transmission 
electron micrograph details the structure of n-type doped silicon nanowires. (C) 
Nanowired hiPSC cardiac spheroids assemble by Day 0 in non-adhesive agarose molds. 
(D) Transmission electron micrograph of spheroid section depicts nanowire location in 
extracellular space; asterisk - nanowire location, triangle – cell membrane. (E) The 
timeline of in vitro conditioning indicates specified electrical stimulation parameters 
and time points. Electrical stimulation and nanowires do not significantly change 
spheroid assembly indicated by consistent (F) spheroid size and (G) laminin expression; 
dotted line represents spheroid edge; red-laminin, yellow-silicon nanowires. NC-D0 - 
unwired and unstimulated at Day 0; NC – unwired and unstimulated at Day 19; WC – 
wired and unstimulated at Day 19; NS – unwired and stimulated at Day 19; WS – wired 
and stimulated at Day 19. 
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(NC) spheroids, unstimulated and wired (WC) spheroids, stimulated and unwired (NS) 
spheroids, and stimulated and wired (WS) spheroids. The nanowired hiPSC cardiac 
spheroids were prepared as described in our previous study.45 Briefly, n-type SiNWs 
(Diameter ≈ 100 nm; length ≈ 10 m; Silane/Phosphane = 500) were mixed with hiPSC-
CMs at a ratio 1:1 and seeded into agarose microwells to prepare nanowired spheroids 
(Figure 2.1A-2.1C). The length of the e-SiNWs was selected to inhibit cell internalization 
(Figure 2.1D), and the doping ratio and diameter of the e-SiNWs were chosen to obtain a 
high conductivity (150 - 500 S/m) to create highly electrically conductive 
microenvironments within spheroids.44,202 While unstimulated (i.e., NC and WC) 
spheroids showed spontaneous beating, stimulated (i.e., NS and WS) spheroids displayed 
successful pacing throughout the entirety of the experiment. High viability validated the 
biocompatibility of silicon nanowires and electrical stimulation condition for prolonged 
spheroid culture (Figure 2.6A, 2.6B). Constant decrease in spheroid size and uniform 
laminin production indicated similar microtissue formation processes among each 
condition (Figure 2.1F, 2.1G, 2.6C). 
Electrical stimulation and nanowires improve cell-cell junctions. Proper 
propagation of electrical and mechanical signals in the heart is a tightly regulated process 
dependent on functional cell-cell junctions between cardiomyocytes. Functionally mature 
human cardiomyocyte junctions develop throughout postnatal childhood and are 
characterized by localized expression of electrically conductive channel proteins, such as 
connexin-43 (Cx43), supported by mechanical junction proteins, such as N-cadherin (N-
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cad) and Zonula Occludens-1 (ZO-1).213-216 As shown in the Figure 2.2A-E, all the treatment 
groups showed significantly improved expression of cellular junctions (i.e., Cx-43 and N-
cad) than NC-D0 spheroids, which indicates the benefits of prolonged microtissue culture. 
In addition, WC and NS spheroids showed the enhanced expression of phenotypic 
immunofluorescent Cx43 punctii per nuclei when compared with unwired, unstimulated 
NC spheroids at D19 (Figure 2.2A, 2.2B), indicating the beneficial role of nanowires and 
electrical stimulation in the formation of electrically conductive cellular junctions. 
 47 
Further, significantly more Cx43 expression was found in the WS spheroids than both WC 
and NS spheroids and demonstrated the synergy between nanowires and electrical 
stimulation. Also, the WS spheroids showed a significant increase in N-cad expression per 
nuclei when compared with the remaining groups (Figure 2.2C, 2.2D). The expression of 
Cx43 and N-cad per nuclei allowed for the development of a cellular junction index that 
supports the synergy of electrical stimulation and nanowires in WS spheroids for 
cardiomyocyte junction formation (Figure 2.2E). Colocalized staining of Cx43 with N-cad 
and ZO-1 in WS spheroids showed not only expression of key junction proteins but also 
suggests functional cardiomyocyte junctions for enhanced electrical and mechanical 
coupling (Figure 2.2F). Enhanced junction formation seen in WS spheroids may facilitate 
their stable integration upon coupling with the host myocardium after transplantation. 
Enhanced contractile development in electrically stimulated, nanowired 
spheroids. Improved junction formation supports cardiomyocyte coupling for contractile 
signal propagation. Spheroids were sectioned and stained with alpha sarcomeric actinin 
Figure 2.2 (previous page). Synergistic contribution of electrical stimulation and 
nanowires to cellular junction formation. (A and B) Connexin-43 (Cx43) 
immunofluorescent staining shows an increased number of phenotypic punctii per 
nuclei in stimulated conditions; red-Cx43, yellow-nanowires; + = significant difference 
with NC-D0, * = significant difference with unstimulated spheroids (p<0.05). (C and D) 
N-cadherin (N-cad) expression shows significantly higher staining per nuceli at the 
intercellular border in WS spheroids; green-N-cad, yellow-nanowires; * - significant 
difference (p<0.05). (E) The junction index is the product (i.e., size of the circle) of the 
normalized (to NC-D0) Cx43 and N-cad expression per nuclei and represents the 
synergistic benefit in WS for cellular junction formation. (F) Representative staining 
for WS spheroids shows colocalization of Cx43 with N-cad and ZO-1 (Zonula 
Occludens-1), suggesting formation of functional cardiomyocyte junctions. NC-D0 - 
unwired and unstimulated at Day 0; NC – unwired and unstimulated at Day 19; WC – 
wired and unstimulated at Day 19; NS – unwired and stimulated at Day 19; WS – wired 





(αSA) to visualize the sarcomeric organization, the structural units that support 
cardiomyocyte contraction. Consistent with the cell-cell junction staining, all the 
treatment groups showed significantly more αSA-stained structures than that of NC-D0 
spheroids (Figure 2.3). In addition, WC and WS spheroids showed enhanced αSA-positive 
structures compared to NC and NS spheroids, while electrical stimulation alone (i.e., NS) 
did not change the amount of αSA-positive structures significantly from NC spheroids 
Figure 2.3. Nanowires influence sarcomeric organization in hiPSC cardiac spheroids. 
(A) αSA immunofluorescent staining shows minimal sarcomeric organization at Day 0. 
(B-F) All conditions showed significantly increased αSA-stained structures at Day 19 
compared to NC-D0. The addition of nanowires further increases αSA expression 
based on αSA-positive area per spheroid area. green- αSA, blue-DAPI nuclear stain. 
(G and H) High magnification αSA-stained images and qualitative scoring show 
highest quality of sarcomere formation in WC and WS spheroids. + = significantly 
different from other groups; * = significantly different from unwired groups (p<0.05). 
NC-D0 - unwired and unstimulated at Day 0; NC – unwired and unstimulated at Day 
19; WC – wired and unstimulated at Day 19; NS – unwired and stimulated at Day 19; 
WS – wired and stimulated at Day 19. 
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(Figure 2.3A-F). Further, high magnification αSA images showed visible formation of 
sarcomeric banding in WC and WS spheroids and a lack of sarcomeric banding in NS 
spheroids (Figure 2.3G, 2.3H). This finding supported the critical role of e-SiNWs to 
improve contractile protein organization in electrically stimulated hiPSC-CM spheroids. 
This was further supported by the significant increases in expression of the sarcoplasmic 
reticulum ryanodine receptor (RYR2) in the WC and WS spheroids (Figure 2.7), which 
regulates intracellular calcium release required for cardiomyocyte contraction. 
The benefits of nanowires for improved contractile characteristics were consistent 
with the genotypic and phenotypic characterization of treated hiPSC-CM spheroids. 
Genetically, the nanowired spheroids (i.e., WC, WS) exhibited increased ratio of beta 
myosin heavy chain (β-MHC; MYH7) to alpha myosin heavy chain (α-MHC; MYH6) (Figure 
2.4A). Individually, β-MHC expression increases significantly compared to Day 0 in 
nanowired groups, while α-MHC did not change significantly (Figure 2.7). This isoform 
trend is consistent with in vivo maturation of human cardiomyocytes and the nonfailing 
adult human heart.24,217 The increase in β-MHC/α-MHC gene ratio has been reported to 
translate to the myosin protein shift and favors lower cellular ATPase activity.218-220 This 
property may be an energetically favorable condition for transplanting cells into the 
energy-limited conditions of a damaged heart. In contrast, the NS group showed 
significantly lower β-MHC/α-MHC ratio compared to the other groups. This suggests a 
limitation of electrical stimulation alone for contractile development of hiPSC cardiac 
spheroids. These findings were supported by immunofluorescent analysis of cardiac 
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troponin I (cTnI), a key indicator of contractile protein maturation (Figure 2.4B, 2.4C). 
While nanowired spheroids showed the improvement in cTnI expression when compared 
with their unwired spheroids, the electrical stimulation alone lead to the reduced cTnI 
expression. The significantly higher density of cTnI in the WS spheroids indicated a critical 
role of nanowires in promoting contractile development of hiPSC cardiac spheroids under 
electrical stimulation.221,222   
Figure 2.4. Nanowires and electrical stimulation affect development of contractile 
machinery in hiPSC cardiac spheroids. (A) Nanowires increase the ratio of beta myosin 
heavy chain (MYH7) to alpha myosin heavy chain (MYH6) expression, and NC, WC, 
and WS show statistical significance compared to NS. (B and C) Immunofluorescent 
expression of cardiac troponin I (cTnI) shows significant increases in nanowired 
conditions, indicating signs of contractile machinery maturation; red-cTnI. * = 
significant difference from marked or remaining groups (p<0.05). NC-D0 - unwired and 
unstimulated at Day 0; NC – unwired and unstimulated at Day 19; WC – wired and 
unstimulated at Day 19; NS – unwired and stimulated at Day 19; WS – wired and 
stimulated at Day 19. 
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Subtype specification of hiPSC-CM using electrical stimulation and nanowires. 
While current hiPSC-CMs are composed of heterogeneous subpopulations (i.e., 
ventricular-like, atrial-like, nodal-like cardiomyocytes), the observed improved contractile 
machinery suggests a shift towards a working myocardial phenotype. Specifically, 
electrical stimulation of hiPSC cardiac spheroids significantly increased ventricular myosin 
light chain (MYL2) over unstimulated spheroids (Figure 2.5A, left). No change was 
observed in atrial myosin light chain (MYL4), indicating an increase in overall ventricular-
like contractile genotype of stimulated spheroids (Figure 2.5A). This was further 
supported with ventricular myosin light chain immunofluorescent staining (MLC-2v), 
showing significantly higher density of MLC-2v expression per spheroid in the WS 
condition (Figure 2.5B, 2.5C). This suggests that exogenous electrical stimulation may 
override the endogenous spontaneous electrical signals in hiPSC-CMs to regulate 
contraction in a pacemaker-like manner and promote the ventricular-like shift.  
The observed shift in cardiomyocyte subpopulation characterization was further 
explored using beat rate analysis to examine hiPSC-CM spheroid function. Each spheroid 
condition was characterized by spontaneous beating throughout the entirety of the 
experiment. While the newly formed NC-D0 spheroids had an average beat rate (± s.e.m.) 
of 35.5±3.0 beats per minute (bpm), all the treatment groups showed a reduced 
spontaneous beat rate. With the 1 Hz stimulation treatment, the spontaneous beat rate 
of NS and WS spheroids significantly decreased to 24.5±2.4 and 25.6±2.8 bpm in 
comparison with NC and WC spheroids (30.4±3.4 and 29.2±3.9 bpm, respectively) (Figure 
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2.5D). The potential mechanism of this functional change due to an exogenous electrical 
field was explored using genetic analysis of ion channels known to be related to the 
spontaneous beating of hiPSC-CMs.24,223 HCN4 is the dominant form of the HCN protein 
in nodal cells and contributes to the pacemaking mechanism of the sino-atrial node.24 
HCN4 is expressed during fetal ventricular expression but is down-regulated in the 
working myocardium during development and virtually absent in adults.224 When 
Figure 2.5. Electrical stimulation and nanowires directly affect subpopulation 
specification and beating properties in hiPSC cardiac spheroids. (A) Electrical 
stimulation significantly improves gene expression of ventricular myosin light chain 
(MYL2), while atrial myosin light chain (MYL4) is unchanged. (B and C) 
Immunofluorescent staining of the MYL2 protein, MLC-2v, supports genetic trend 
with significantly more expression per area in WS; red-MLC-2v. (D) Electrical 
stimulation significantly reduced the spontaneous beat rate of hiPSC cardiac 
spheroids compared to unstimulated and NC-D0 spheroids. + = significantly different 
from NC-D0; * = significantly different from unstimulated groups (p<0.05). (E) 
Electrical stimulation significantly reduced the mRNA expression of HCN4, a 
pacemaker gene in the adult heart. The presence of nanowires preserved KCNJ2 
expression when under stimulation, an important gene to prevent spontaneous 
contraction in adult ventricular cardiomyocytes. * = significantly different from 
unmarked groups. NC-D0 - unwired and unstimulated at Day 0; NC – unwired and 
unstimulated at Day 19; WC – wired and unstimulated at Day 19; NS – unwired and 
stimulated at Day 19; WS – wired and stimulated at Day 19. 
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compared with unstimulated spheroids, electrical stimulation significantly reduced HCN4 
expression, suggesting a shift away from a pacemaker-like genotype (Figure 2.5E, left). 
This decrease in HCN4 expression combined with a functional decrease in beat rate 
indicates a critical role of electrical stimulation in the regulatory mechanism governing 
hiPSC-CM spheroid electrical properties. Furthermore, the lack of inward rectifying 
channel (KCNJ2) expression has been shown to contribute to the spontaneous beating 
phenomenon in hiPSC-CMs.23,225 Notably, under electrical stimulation, the addition of e-
SiNWs to hiPSC cardiac spheroids was critical to preserve inward rectifying channel 
(KCNJ2) gene expression (Figure 2.5E, right). Interestingly, the significant decrease in 
KCNJ2 gene expression in NS is in line with the limited contractile development of NS 
discussed above. Nevertheless, electrical stimulation can synergize with e-SiNWs to 
provide exogenous and endogenous cues to affect the cardiomyocyte subpopulation 
specification and significantly decrease the spontaneous beat rate of hiPSC-CM spheroids. 
Notably, HERG (KCNH2) showed no significant changes with electrical stimulation at 1 Hz, 
which is consistent with the recent studies conducted by Eng and coworkers (Figure 2.7). 
They reported an up-regulated HERG expression with a 2 Hz stimulation treatment and 
un-changed HERG expression with 1 Hz stimulation.39 
 
Conclusion 
To date, transplantation of hiPSC-CMs into damaged hearts have led to limited 
improvements in heart functions and increased risk of arrhythmia.115,226-228 These results 
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alongside recent research showing enhanced cell retention using cellular aggregates 
indicate that hiPSC-CM microtissues with advanced cellular development provide an 
attractive cell delivery system for transplantation.114,229,230 Our previous research showed 
that addition of e-SiNWs to hiPSC cardiac spheroids creates an electrically conductive 
microenvironment and significantly improves the structural and functional development 
of hiPSC cardiac spheroids.45 In this study, we demonstrated that the addition of 
nanowires to the spheroids is essential for the utilization of electrical stimulation to 
improve the functions of hiPSC cardiac spheroids. With nanowires, exogenous electrical 
stimulation increases cell-cell junction formation (i.e., Cx-43 and N-cad), improves 
development of contractile machinery (i.e., sarcomeric structure, β-MHC/α-MHC gene 
ratio and cTnI expression), and preserves KCNJ2 gene expression. In contrast, electrical 
stimulation alone (i.e., NS) showed increased Cx43 yet lower N-cad along with reduced 
sarcomere development, cTnI expression, β-MHC/α-MHC gene ratio, and KCNJ2 gene 
expression.  Although it has been reported that electrical stimulation alone can advance 
cardiomyocyte development in vitro, the data presented here suggests potential 
limitations of the use of electrical stimulation without nanowires in hiPSC cardiac 
spheroids for ventricular applications.  
Remarkably, electrical stimulation of nanowired spheroids also resulted in a 
significant reduction in endogenous, spontaneous beat rate and shifts in cardiomyocyte 
subpopulation characterization. These phenomena point to the beneficial functional and 
genomic effects of exogenous electrical stimulation to affect the endogenous electrical 
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properties of nanowired hiPSC cardiac microtissues. The observed reduction of 
spontaneous beat rate and pacemaker-like genotype clearly demonstrates tissue level 
functional development that would be beneficial for reduced pacemaking/arrhythmic risk 
after transplantation. 
In conclusion, we demonstrated, for the first time, that the combination of e-
SiNWs and electrical stimulation synergistically improves cell junction formation, 
increases contractile properties, and reduces the endogenous spontaneous beat rate of 
hiPSC-CM spheroids. Enhancing the cell-cell junctions of hiPSC cardiac spheroids in vitro 
may lead to improved cellular integration and functional contribution after 
transplantation. The increased expression of contractile machinery in vitro indicates an 
increased cardiomyocyte developmental age, which has been shown to be advantageous 
for transplantation.31,231 Given that many cardiac cell therapies target ventricular 
myocardial repair, the observed expression shift towards the ventricular isoform of 
myosin light chain shows promise for improved functional integration. Likewise, by 
decreasing the spontaneous beat rate in hiPSC cardiac spheroids and directly effecting 
genes that regulate the spontaneous beating of hiPSC-CMs, we propose that this in vitro 
conditioning model will reduce the arrhythmogenic risk of hiPSC-CMs. In addressing these 
underdeveloped properties of hiPSC-CMs with the combination of endogenous 
nanomaterials and exogenous stimuli, we hope to contribute to the next generation of 
cell therapy approaches for cardiac repair. 
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Materials and Methods 
Electrically conductive silicon nanowire fabrication and harvesting. Consistent 
with our previous work, single-crystalline SiNWs were synthesized using the nanocluster-
catalyzed vapor-liquid-solid method described previously in a quartz tube connected to a 
gas manifold and vacuum pump and heated by a temperature controlled tube furnace.232 
Monodisperse gold nanoparticles (100 nm, Ted Pella) were dispersed on SiO2/silicon 
substrates, which were placed within the central region of the quartz tube reactor. The 
SiNWs were synthesized at 470-485 oC using silane (SiH4) as the silicon reactant source, 
H2 as the carrier gas, and phosphine (PH3, 1000 ppm in H2) as the n-type dopants, 
according to the previously established protocol.201 The length and diameter of the e-
SiNWs were selected to inhibit cell internalization. The doping ratio with a 
silane/phosphine ratio of 500 was chosen to obtain a high conductivity (150 - 500 S/m) 
compared to cell culture medium (~1.75 S/m) and myocardium (~0.1 S/m) to create 
highly electrically conductive microenvironments within spheroids.44,202 In a typical 
synthesis of uniform n-type, 100 nm SiNWs, the flow rates of SiH4, PH3 and H2 were 1-2, 
2-4 and 60 standard cubic centimeters per minute, respectively, and the total pressure 40 
torr. The nanowires were collected from the oxidized silicon substrates by sonication in 
isopropanol for 1 min followed by centrifugation to obtain SiNWs with an average 
dimension of 100 nm diameter and 10 µm length. The electrical conductivity of the SiNWs 
were measured by using four-probe transport measurement.  
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hiPSC-CM cell culture. Human induced pluripotent stem cell-derived 
cardiomyocytes (hiPSC-CMs) (iCell Cardiomyocytes, Cellular Dynamics International-CDI, 
Madison, WI, USA) were cultured according to the manufacturer's protocol. Briefly, hiPSC-
derived cardiomyocytes were plated on 0.1% gelatin coated 6-well plates in iCell 
Cardiomyocyte Plating Medium (CDI) at a density of about 3 × 105 to 4.0 × 105 cells/well 
and incubated at 37 °C in 5% CO2 for 4 days. Two days after plating, the plating medium 
was removed and replaced with 4 mL of iCell Cardiomyocytes Maintenance Medium (CDI). 
After 4 days of monolayer pre-culture, cells were detached using trypLE Express (Gibco 
Life Technologies, Grand Island, NY) and prepared for spheroid fabrication.  
Spheroid fabrication and electrical stimulation. As described in our previous 
publication,45 the agarose hydrogel molds were prepared using autoclaved 2% agarose 
(Sigma Aldrich, St. Louis, MO) and commercial master micro-molds from Microtissues, Inc 
(Providence, RI) as negative replicates to create non-adhesive agarose hydrogels molds 
containing 35 concave recesses with hemispheric bottoms (800 m diameter, 800 m 
deep) to facilitate the formation of tissue cell spheroids. A suspension of hiPSC-derived 
cardiomyocytes were mixed with e-SiNWs in media at a 1:1 ratio (number of cells:number 
of SiNWs) for a final concentration of 2.0 x 106 cells/mL. Approximately 75 µl of the cell/e-
SiNW suspension was pipetted into each agarose mold.  After the cells settled into the 
recesses of the mold (10 min), additional media was added to submerge the molds in an 
8-well plate and exchanged every 2 days for the length of the experiment. Day 0 of the 
experiment was marked after 4 days of spheroid assembly. Electrical stimulation (C-Pace 
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unit, Ion Optix, Milton, MA) was started on Day 10 (2.5V/cm, 5 ms). A ramp-up method 
(Day 1 – 0.5 Hz, Day 2 – 0.75 Hz) was used to bring the frequency of stimulation to 1 Hz 
for the remainder of the experiment. Here, Day 19 represents 7±1 days of stimulation at 
1 Hz. A scheme of the experimental setup is found in Figure 2.1A and 2.1B. 
Beat rate analysis of beating spheroids. Videos of spontaneously beating 
spheroids from each group were recorded at room temperature (after temperature 
stabilization) without stimulation for each condition starting on Day 0 using Zen 2011 
software (Zeiss, Göttingen, Germany). Videos were converted to a series of TIFF format 
pictures by Adobe Premiere (Adobe, San Jose, CA). Threshold edge-detecting in ImageJ 
software (National Institutes of Health) was used on high contrast spheroid picture series 
and graphed to realize beating profiles, from which beats per minute was calculated 
(n=15-50 spheroids). Diameter of each spheroid was calculated from the threshold-based 
area of high contrast spheroid images (n=15-50 spheroids).  
Immunofluorescent analysis. Freshly collected spheroids were flash frozen in 
Tissue-Tek OCT compound (Sakura, Torrance, CA). Embedded spheroids were 
cryosectioned into 7 µm thickness layers onto glass slides for immunohistochemistry. The 
sections were fixed with pre-cooled acetone (-20 °C) for 10 min. After washing (2 times at 
5 min) in PBS with 0.1% Triton X-100 (PBST) (Sigma), blocking buffer was made with 10% 
serum corresponding to host species of secondary antibody in PBST and added to sections 
for 1 hr at room temperature. Sections were incubated with primary antibody diluted in 
PBST (1:200): laminin (Sigma), connexin-43 (Sigma), N-cadherin (BD Biosciences, San Jose, 
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CA), ZO-1 (Thermo Fisher Scientific, Waltham, MA), alpha sarcomeric actinin (Abcam, 
Cambridge, UK), cardiac troponin I (Abcam), MYL2 (Abcam) overnight at 4 °C or 2 hrs at 
room temperature. After washing in PBST (2 times at 5 min), tissues were incubated with 
complement secondary antibodies diluted in PBST for 1 hr at room temperature. After 
washing in PBST (2 times at 5 min), nuclei were counterstained with DAPI (Molecular 
Probes/Invitrogen, Eugene, OR) diluted in PBST for 15 min at room temperature. 
Following the final wash procedure (PBST, 2 times at 5 min), glass cover slips were added 
to the slides using Fluoro-Gel (Electron Microscopy Sciences, Hatfield, PA) and slides were 
stored in 4 °C. TCS SP5 AOBS laser scanning confocal microscope (Leica Microsystems, 
Inc., Exton, PA) was for imaging. Fluorescent protein expression was calculated as the 
antibody-positive fluorescence area coverage divided by the number of nuclei or spheroid 
area. Each analysis consisted of 2-3 high resolution images at 400X total magnification of 
3-5 spheroids to obtain an accurate representation of the entire spheroid. 
TUNEL staining for frozen spheroids section. Roche In Situ Cell Death Detection Kit 
(Sigma) was used to determine the viability of cells in the frozen sections of spheroids 
based on the Roche protocol. Briefly, the frozen sections of spheroids were fixed with 4% 
paraformaldehyde in PBS for 20 min at room temperature. Following washing in PBS for 
30 minutes, samples were incubated in a permeabilization solution (0.1% Triton X-100 
and 0.1% sodium citrate in PBS) for 2 minutes on ice. Then 50 µl of the TUNEL reaction 
mixture were added to samples and incubated at 37 °C for 1 hr. After washing in PBS (2 
times at 5 min), nuclei were counterstained with DAPI (Molecular Probes/Invitrogen) 
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diluted in PBS for 15 min at ambient temperature. Following the final wash procedure 
(PBS, 2 times at 5 min), glass cover slips were added to the slides using Fluoro-Gel 
(Electron Microscopy Sciences). TCS SP5 AOBS laser scanning confocal microscope (Leica 
Microsystems) was used for imaging.  
Gene expression with qRT-PCR. Total RNA was isolated according to the kit and 
protocol of an RNeasy Micro Kit (Qiagen, Vinlo, Netherlands) with the addition of the 
Homogeneizer Columns (Omega Biotek, Norcross, GA) during the homogenization step 
for spheroids. For each group, a minimum of 15 spheroids were used for RNA isolation. 
At least 25 ng of total RNA for each group was subjected to cDNA synthesis using the Bio-
Rad (Hercules, USA) iScript cDNA synthesis kit. qRT-PCR step was performed using 
validated Life Technologies Taqman primers (Thermo Fisher Scientific) in 10 μl reactions 
for the targeted genes listed in Table S1. Data was normalized as the change in cycle 
threshold (Ct) to the geometric mean of GAPDH and ACTB (dCt) and analyzed using, mRNA 
expression = 2^(-dCt). Data was then normalized to NC-D0 gene expression and averaged 
across n=3 experiments. 
Statistics Analysis. Differences between experimental groups were analyzed using 
one-way and two-way ANOVA and Tukey’s post-hoc test, and p<0.05 was considered 








Figure 2.6. hiPSC cardiac spheroid assembly. (A) TUNEL staining of frozen spheroid 
sections show high viability; blue-DAPI nuclear stain, green-TUNEL apoptotic nuclei. 
(B) Quantification of TUNEL-based viability shows high viability among all groups. (C) 
Laminin immunofluorescent staining reveals consistent laminin production 
throughout the whole spheroid in each condition; red-laminin, yellow-nanowires. NC-
D0 - unwired and unstimulated at Day 0; NC – unwired and unstimulated at Day 19; 
WC – wired and unstimulated at Day 19; NS – unwired and stimulated at Day 19; WS 







Figure 2.7. Gene expression analysis of hiPSC cardiac spheroids. The analyzed genes 
correspond to the following aliases: MYH6 – alpha myosin heavy chain; MYH7 – beta 
myosin heavy chain; RYR2 – ryanodine receptor; KCNH2 – HERG channel. + = 
significantly different with Day 0; * = significantly different from remaining groups 
(p<0.05). NC – unwired and unstimulated at Day 19; WC – wired and unstimulated at 




Taqman primers used for gene analysis. 
Gene symbol Primer ID 
ACTB Hs01060665_g1  
GAPDH Hs02758991_g1   
GJA1 Hs00748445_s1  
HCN4 Hs00975492_m1  
KCNH2 Hs04234270_g1  
KCNJ2 Hs01876357_s1  
MYH6 Hs01101425_m1  
MYH7 Hs01110632_m1  
MYL2 Hs00166405_m1  
MYL4 Hs04187281_m1  









With the advancement of human induced pluripotent stem cell technologies, the 
emerging human organoids have provided a powerful platform to model human organ 
development and pathologies, as well as provide cell delivery systems for regenerative 
therapy.57,58 Organoids are 3D structures based on the self-organization of stem cell-
derived organ-specific cell types to recapitulate major tissue/organ structures and 
functions. To this end, the development of a variety of functional human organoids (e.g., 
lung, liver, brain) has given novel insight into developmental and pathological 
processes.56,89,233-235 Despite the increasing progress in other organ systems, few studies 
have focused on the development of a human cardiac organoid.236,237 Recapitulation of 
the 3D multicellular structure and function of the developing myocardium remains a 
challenge for the development and application of human cardiac organoids.238 
Significant advancements, however, have been made in the utilization of human 
induced pluripotent stem cell derived-cardiomyocytes (hiPSC-CMs) at the cellular and 
genetic level for the development of disease models and drug screening systems.96,239,240 
In addition to 2D culture systems, significant resources have been devoted to developing 
3D myocardial constructs to support cardiomyocyte development and improve viable 
transplantation approaches.241 Strategies have been engineered to target specific 
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physiologically relevant features (e.g., multicellular, capillary-like diffusion, electrical 
stimulation) in the myocardium to improve cardiomyocyte functions and 
development.39,46,48-51,242,243 To this end, early cardiac tissue engineering efforts, such as 
the work of Kelm and others, demonstrated that cardiac spheroids made from a mixed 
cell population derived from neonatal/fetal rodent hearts supported myocardial 
extracellular matrix profile and cardiomyocyte sarcomere development.29,244 This has 
been supported further by several hiPSC-CM-based studies showing that supporting cell 
types provide extracellular matrix microenvironment, incorporate angiogenic signaling, 
enhance microtissue assembly, and improve maturation of cardiac microtissues.53-55,245-
248 Furthermore, the addition of vascular cell types to cardiac microtissues can model 
aspects of coronary angiogenesis and provide a functional benefit in heart repair by 
connecting to the host vasculature after transplantation.51,244,248,249 By targeting specific 
hiPSC-CM functions/properties, tissue-engineered cardiac systems have been 
advantageous for the development of more sensitive drug testing models and improved 
cell delivery strategies. However, by using “output” structures/functions as the input 
design principle, these platforms can exclude tissue/organ-level intricacies that are critical 
for modeling cardiac development and pathologies.  
While cardiac differentiation of embryoid bodies holds great potential for 
cardiovascular organoid production236,237, the intramyocardial organization events in 
coronary vasculogenesis provides the biological inspiration for a method of controlled, 
scaffold-free human cardiac organoid fabrication using defined cell types. In 
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development, after the 4-chamber heart structure has formed, the formation of the 
epicardium involves a dynamic process of epithelial-mesenchymal transition of 
epicardium-derived cells that migrate into the myocardium and differentiate into vascular 
and cardiac interstitial cell types.250-252 Subsequently, the developing ventricular 
myocardium undergoes the intramyocardial organization events of coronary 
vasculogenesis where a diverse, yet defined, mixture of cardiac cell types (e.g., 
cardiomyocytes, cardiac fibroblasts, vascular cell types) organize into functional 
myocardium before anastomosis to the aorta (Figure 3.1A, 3.1B).253-256 At this point in 
development, the cardiomyocytes also retain a spontaneous beating property, in part, 
due to incomplete sub-type specification of the cardiomyocytes, similar to hiPSC-CMs.24,30 
Inspired by these events and the developing/immature characterization of hiPSC-CMs, we 
have established a defined, scaffold-free fabrication strategy to assemble vascularized 
human cardiac organoids in vitro that recapitulate an array of structural, genetic, and 
functional cardiac tissue-level characteristics of the developing myocardium. Through 
incorporation of the events of coronary vasculogenesis as the major design principle in 
human cardiac organoids, the technology described here provides a powerful platform to 
incorporate and investigate the cellular, matrix/material and additional factors required 
to promote tissue/organ-level heart development. Furthermore, this platform lays down 
the foundation for the development of functional cardiac tissues for tissue-/organ-level 
drug screening and advanced cell therapy for heart repair. 
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Results and Discussion 
Developmental inspiration for cardiac organoid fabrication. The dynamic cellular 
organization events of coronary vasculogenesis during heart development (after the 4-
chamber structure as formed) provided a developmental basis for the fabrication of 
cardiac organoids, represented in Figure 3.1A. To prepare human cardiac organoids, we 
Figure 3.1. Developmental inspiration for organoid fabrication. (A) In the developing 
heart after the 4-chamber structure has formed, the epicardium and subsequent 
epithelial-to-mesenchymal transition give rise to a diverse mixture of cardiac cell types. 
This stage of intramyocardial organization marks the initial phase of coronary 
vasculogenesis. The self-assembly process surrounding this intramyocardial 
organization served as inspiration for analogous, self-assembled cardiac organoids 
from a defined mixture of cardiac cells prior to blood flow. (B) Hematoxylin and eosin-
stained mouse embryonic heart sections at embryonic day 13.5 (E13.5) show the 4-
chamber structure and the epicardium adjacent to the developing ventricular 
myocardium (inset). By E15.5 (right), evidence of preliminary coronary vessels 
(asterisk) can be seen in the developing ventricular myocardium. 
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utilized hiPSC-CMs, human ventricular cardiac fibroblasts (cFBs) and human umbilical vein 
endothelial cells (HUVECs) to represent the major cardiac cell types in the developing 
myocardium. Due to their immature characteristics, hiPSC-CMs served as an appropriate 
cell type to represent cardiomyocytes in the developing myocardium.24 While aligned 
cardiac microtissue research has significantly enhanced the understanding of stem cell-
derived cardiomyocyte mechanical/electrical properties (e.g., contraction force, 
conduction velocity)21,48,243,257,258, the cardiac organoid system does not incorporate an 
aligned cardiomyocyte design to resemble the developing heart at the stage of coronary 
vasculogenesis, in which significant anisotropic cardiomyocyte organization has not been 
established (Figure 3.1B). During the spheroid fabrication, the ratio between different 
cardiac cells was selected to approximate cell ratios in developing hearts (5:4:1, hiPSC-
CMs:cFBs:HUVECs).259-261 As an alternate rationale, human cardiac organoids were also 
fabricated using the ratio of cells corresponding to adult hearts (3:6:1, hiPSC-
CMs:cFBs:HUVECs) (Figure 3.2A-C).259-261 The experimental timeline can be seen in Figure 
3.8.  
By experimental Day 10 (D10), the developing stage ratio cardiac organoids 
showed significantly higher contraction amplitude (i.e., fractional area change) and 
regularity of beating than adult ratio organoids, which was attributed in part to the higher 
hiPSC-CM composition in the developing stage ratio organoids (Figure 3.2D, 3.2E). In 
addition, the difference in the contraction profiles was supported by enhanced sarcomere 
development (e.g., Z-line formation) in developing stage ratio organoids at D10 when 
 69 
compared to adult ratio organoids, which have minimal Z-line formation despite still 
having alpha sarcomeric actinin (α-SA)-positive regions (Figure 3.9). This suggested that 
the developing stage ratio provided a favorable microenvironment for hiPSC-CM 
Figure 3.2. Examination of developmental inspiration for cardiac cell ratio for organoid 
fabrication. (A) The ratio of cardiac cell types (by number) changes throughout 
development, based on reported literature ref. 259-261. (B, C) A developing stage and 
adult stage cell ratios of cardiac cell types represent two organoid fabrication 
rationales to support cardiomyocyte development, seen in bright-field images at D0; 
n=human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM), human 
cardiac ventricular fibroblasts (cFB), human umbilical vein endothelial cells (HUVEC). 
(D) Representative contraction profiles for developing stage and adult stage ratio 
organoids were constructed from video analysis of spheroid fractional area change. (E) 
Analysis of average (±SEM) contraction amplitude (i.e., fractional area change) showed 
significant differences at D10; n=8-12 organoids. Developing stage ratio organoids 
showed 100% of organoids beating at D10, while adult stage ratio organoids had only 
~50% beating. Asterisk represents significant difference, p<0.05. 
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development and supported the developmental basis for cardiac organoid fabrication. 
This finding is consistent with previous engineered findings showing that cardiac 
constructs containing a majority of cardiomyocytes of the construct supports increased 
hiPSC-CM functions.32,39,48,243 The developing stage cell ratio for cardiac organoids was 
used for the remainder of the experiments. 
To examine the effects of media components on organoid formation and 
maturation, DMEM/F12 media with varying amounts of FBS was prepared and compared 
to a ratiometric combination of cardiomyocyte media (DMEM/F12, 10% FBS), fibroblast 
media (FGM-3, defined growth factors, 10% FBS), and endothelial cell media (EGM-2, 
defined growth factors, 2% FBS) corresponding to the cell ratio (Figure 3.10). After 4 days 
of organoid formation, the cardiac organoids with the ratiometric combination showed 
significantly better viability index (i.e., reduced TUNEL-positive apoptotic nuclei) and was 
used for the remainder of the experiments. 
Phenotypic cellular behavior in human cardiac organoids. Immunofluorescent 
analysis using von Willebrand factor (vWF) and CD31 endothelial markers of the cardiac 
organoids revealed limited staining and spreading of HUVECs at D0 through D10 (Figure 
3.3A). Human adipose-derived stem cells (hADSCs) were added to the cardiac organoid 
system to promote endothelial function based on their pericyte-like function and pro-
angiogenic properties.161,262-267 Cardiac organoids with hADSCs were fabricated with 50% 
hiPSC-CMs, 29% cFBs, 14% HUVECs, and 7% hADSCs. The relative amount of hADSCs 
reflects the limited amount of pericytes in the heart, supported by previous research in 
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endothelial-ADSC co-culture systems (Figure 3.3B).245,262 The effects of hADSCs were 
noticeable from D0 by enhanced organization of vWF-positive cells (i.e., HUVECs) in a 
circular pattern surrounding the inner portion of the organoid (Figure 3.3A). By D10, the 
addition of hADSCs increased indications of enhanced endothelial function and/or 
viability, described by the increased covered area of vWF-positive structures, and 
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promoted EC network formation in cardiac organoids compared to without hADSCs, as 
shown by vWF and CD31 staining (Figure 3.3A, 3.3C).  
As in coronary vasculogenesis, where vascular cell types and cardiac interstitial 
cells form the endothelial plexus in the beating myocardium before connecting to the 
future coronary artery253, lumen-like structures with vWF-positive cells were found within 
the cardiac organoids bordered by α-SA-positive hiPSC-CMs, although not every vWF-
positive cell participated in the lumen formation (Figure 3.3D). Notably, cardiac organoids 
with hADSCs showed significantly more vWF-positive lumen structures than without 
Figure 3.3 (previous page). The addition of human adipose derived stem cells improves 
biomimetic formation of functional, lumenized vascular networks in cardiac organoids. 
(A) The addition of adipose-derived stem cells (+ADSC) led to increased vWF- and 
CD31-positive endothelial network formation by D10. Without human adipose-derived 
stem cells (-hADSC), cardiac organoids showed limited endothelial staining; n=3 
organoids/group per endothelial stain. (B, C) The addition of hADSCs to the 
developmentally inspired cardiac organoid fabrication significantly improved the vWF-
positive area over spheroid area by D10; n=3 organoids. (D) Lumen-like structures 
(asterisk) were observed in D10 cardiac organoids with hADSCs with vWF-positive (red) 
endothelial cells within α-SA-positive (green) hiPSC-CMs areas; blue-DAPI. (E) 
Significantly more vWF-positive lumen structures were observed per organoid in D10 
organoids with hADSCs in comparison to without hADSCs; n=10 organoids per group. 
(F) 3D reconstruction of thick sections of D10 cardiac organoids with hADSCs show 3D 
structure of a CD31-positive (green) vessel with open lumens (asterisk) supported by 
vimentin-positive (red) support cells; blue-DAPI. (G) Evaluation of putative vasculature 
showed (i) that culturing cardiac organoids from D0-D10 (before putative vasculature 
formation) in an oxygen-reduced environment (10% O
2
) for 10 days resulted in a 
significant decrease in viability in the center, indicated by TUNEL apoptosis assay, 
compared to cardiac organoids with formed lumenized vascular networks (D10-D20) 
and D10 and D20 controls (21% O
2
); n=4-7 organoids. (ii) Macrotissue assembly using 
five D10 cardiac organoids cultured 10 days (D10-D20) showed minimal TUNEL 
expression and displayed extensive vWF-positive endothelial networks across the 
whole macrotissue (n=3 macrotissues). Cardiac organoids were fabricated using a 
developing stage cell ratio. Asterisk represents significant difference, p<0.05. 
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hADSCs (Figure 3.3E). 3D reconstruction of thick cardiac organoid sections revealed CD31-
positive vessel structures supported by vimentin-positive cells (Figure 3.3F). Serial images 
of confocal imaging of vWF-stained whole organoids further confirmed the formation of 
multiple areas with lumen-like regions in X, Y, and Z perspectives connected by vWF-
positive ECs (Figure 3.11). The increase in vWF- and CD31-positive structures and lumen 
formation demonstrated the structural functionality of the HUVECs and was largely 
attributed to the pro-angiogenic role of hADSCs. This is supported by a growing amount 
of research indicating a perivascular origin and properties of mesenchymal stem cells 
(e.g., hADSCs), which is consistent with other studies showing the pro-angiogenic 
properties of hADSCs 262-266. In addition, the organizational changes seen after the 
addition of hADSCs is consistent with other multicellular research that indicates a higher 
order level of self-organization beyond differential cell adhesion dynamics.237,268 
Furthermore, vascular endothelial growth factor (VEGF) signaling plays an important role 
during coronary vasculogenesis.269 Gene expression of vascular endothelial growth factor 
A (VEGFA) and the main VEGF-A receptor 2 (VEGFR2) in cardiac organoids and spheroids 
of each individual cell type indicated the potential role in angiogenic signaling within 
cardiac organoids between the major VEGF providers (hiPSC-CMs, cFB, hADSCs) and VEGF 
receiver (HUVECs) (Figure 3.12). 
To evaluate the functionality of the putative vasculature, cardiac organoids were 
placed in an oxygen-reduced environment (10%) before (D0) and after (D10) putative 
vasculature had formed for 10 days. Cardiac organoids cultured at 10% O2 from D0 (before 
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putative vasculature formation) showed a significant increase in TUNEL expression at the 
organoid center when compared to cardiac organoids cultured at 10% O2 from D10 (Figure 
3.3G(i), 3.13). This strongly indicates the formation of putative vasculature reduces cell 
apoptosis in the organoids center, suggesting their function to improve nutrient transport 
within the organoids. In addition, we examined whether the putative vasculature in the 
cardiac organoids can allow for the fabrication of large viable cardiac tissue engineering 
constructs, as oxygen diffusion in the engineered cardiac tissue is limited to a 100-200 µm 
range.270,271 To this end, cardiac organoids were cultured for 10 days to form putative 
vasculature and then placed in groups of five to form organoid aggregates. Macrotissue 
assembly was observed until D20, where the aggregates had formed large macrotissues 
(>200 µm radius) with observable increased Z-dimension. TUNEL analysis showed no 
significant changes in viability by D20 and immunofluorescent staining revealed large 
regions of connected, vWF-positive endothelial cells (i.e., networks) across the organoid 
macrotissues (Figure 3.3G(ii), 3.14). The observed enhanced viability in both cases 
strongly indicates a functional benefit of putative vasculature, which is consistent with 
previous studies incorporating vascular networks in rodent-cell based and scaffold-based 
engineered cardiac constructs for improved viability/integration after transplantation 
and evident from cardiovascular tissue engineering studies showing large necrotic core in 
large scaffold-free constructs without pre-established vasculature.236,272-274 This 
improvement may be attributed to the enhanced passive transport of nutrients whereby 
the presence of lumens creates a porous construct that increases diffusivity to the center 
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of the micro-/macrotissues.275 These data support the functional benefit of recapitulating 
the lumenized vascular network of the developing myocardium in the cardiac organoids. 
To explore the effects of endothelial cell source on the vasculature formation in 
the organoids, we substituted HUVECs with human adipose-derived microvascular 
endothelial cells (HAMECs) to fabricate cardiac organoids due to their 
microvascular/capillary origin in vivo.276 HAMEC cardiac organoids showed some 
evidence of network formation but overall showed less vWF-positive cells than HUVEC 
cardiac organoids on D10, while the cardiomyocyte organization was similar in both cases 
(Figure 3.15). This is consistent with reduced in vivo vascular network density observed in 
Figure 3.4. The addition of human adipose derived stem cells affects biomimetic 
cellular organization and introduces immunomodulatory effects. (A) α-SA-positive 
(green) hiPSC-CMs were mainly located in the outer region of spheroid cross-sections 
with or without hADSCs. The addition of hADSCs showed more homogeneous 
distribution of vimentin-positive (red) cells by D10; blue-DAPI. (B) The density of 
vimentin-positive staining area within α-SA regions significantly increased in cardiac 
organoids with hADSCs; n=3-4 organoids. (C) hADSCs demonstrated 
immunomodulatory role by significantly decreasing the expression of IL6 in cardiac 
organoids with hADSCs; n=3 experiments, 10-15 organoids/experiment. Cardiac 
organoids were fabricated using a developing stage cell ratio.  Asterisk represents 
significant difference, p<0.05. 
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transplanted human dermis-derived microvascular endothelial cells compared to 
HUVECs.277 These results may reflect tissue-specific and/or developmental age properties 
of the cell source that influence their angiogenic/vasculogenic and structural 
functionality.278-281 However, given their facile, readily expandable culture properties and 
consistent vasculogenic characteristics in cardiac organoids, HUVECs were used for the 
remainder of the experiments. 
As for the hiPSC-CM, cFB, and hADSC organization, D0 cardiac organoids with or 
without hADSCs showed heterogeneous populations of vimentin-positive cells (i.e., cFBs 
and hADSCs) throughout the microtissue (Figure 3.4A). The majority of α-SA-positive 
hiPSC-CMs with or without hADSCs organized in the outer regions of the cardiac 
organoids. In the native myocardium, adjacent fibroblast-cardiomyocyte interactions are 
critical for cardiac development.282 By D10, cardiac organoids with hADSCs displayed an 
increased density of vimentin-positive cells in the α-SA-positive (i.e., hiPSC-CMs) regions 
of the cardiac organoid (Figure 3.4A, 3.4B). Furthermore, the immunomodulatory 
potential of hADSCs was supported by a significant reduction in the pro-inflammatory 
interleukin IL6 gene expression in cardiac organoids, compared to organoids without 
hADSCs (Figure 3.4C).283 
Extracellular matrix (ECM) protein production in human cardiac organoids. In 
addition to the phenotypic cellular distribution throughout the cardiac organoid, the 
extracellular matrix proteins in the cardiac organoids supported the development of an 
organotypic microenvironment. One limitation in hiPSC-CM spheroids (i.e., microtissues 
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composed of 100% hiPSC-CMs) is the lack of collagen in the microtissue. While hiPSC-CM 
spheroids showed limited collagen I expression throughout the experiment with 
disconnected, dotted structures, the cardiac organoids expressed significantly more 
collagen I-positive, connected structures indicative of mature, stable collagen fibril 
formation (Figure 3.5A). This difference was attributed to the presence of cardiac 
fibroblasts in the organoids, as collagen is maintained by the cardiac fibroblasts in the 
Figure 3.5. Human cardiac organoids display organotypic extracellular matrix (ECM) 
components. (A) Spheroids comprised of 100% hiPSC-CMs (hiPSC-CM spheroids) 
showed limited, dotted collagen I immunofluorescent staining, while cardiac organoids 
showed significantly increased, connected collagen I structures by D10. (B) hiPSC-CM 
spheroids showed overall low levels of fibronectin expression, while cardiac organoids 
decreased significantly by D10. Quantification of ECM components was based on the 
ratio of ECM-positive covered area divided by total spheroid area. hiPSC-CM-human 
induced pluripotent stem cell-derived cardiomyocyte. Cardiac organoids were 
fabricated using a developing stage cell ratio; n=3-6 microtissues. Asterisk represents 
significant difference, p<0.05. 
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native myocardium.282 As shown in the Figure 3.5A, collagen I expression in the organoids 
increased from D0 to D10, consistent with results from developing hearts.284  
Notably, in cardiac organoids, fibronectin-positive spheroid area decreased 
significantly from D0 to D10, while hiPSC-CM spheroids showed overall low levels of 
fibronectin-positive structures at D0 and D10 (Figure 3.5B). This may suggest the 
formation of non-pathological, ventricular-like extracellular microenvironment to 
support development of hiPSC-CMs, as fibronectin has been shown to be more abundant 
in atrial than ventricular myocardium, and increased ventricular fibronectin is associated 
with pathological cardiac hypertrophy.285,286 The changes in fibronectin in cardiac 
organoids (high to low from D0 to D10) may also indicate the increased role of fibronectin 
during microtissue formation evidenced by the high levels at D0 and/or the observed role 
of fibronectin in myofibril organization in cardiac development.287-290 In addition, the 
basement membrane protein (laminin) is produced by hiPSC-CMs and showed strong 
immunofluorescent expression in both hiPSC-CM spheroids and cardiac organoids 
throughout the experimental timeline (Figure 3.16). Cardiac organoids provide a 
biomimetic matrix environment that supports cardiac function and can serve as a model 
for biomaterial/construct design in exploring the necessary material components for 
cardiac development. 
Enhanced cardiomyocyte development within cardiac organoids. Previous work 
using hiPSC-CM spheroids has indicated conditioning approaches and extended culture 
are required to enhance the contractile properties toward physiological relevance.45,241 
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We next explored the effect of cellular and matrix microenvironment as a biomimetic 
stimulus in the organoids to promote the contractile properties of hiPSC-CM. During the 
Figure 3.6. Human cardiac organoids support contractile development of hiPSC-CMs. 
(A) Cardiac organoids showed signs of improved sarcomere development (e.g., Z-line 
width) by D10 in comparison to hiPSC-CM spheroids. (B) Ratiometric gene expression 
of hiPSC-CM spheroids and cardiac organoids reveal improvements in hiPSC-CM 
development within microtissues. Gene expression of cardiac troponin I (TNNNI3) over 
slow, skeletal troponin I (TNNNI1) showed greater significant increases in cardiac 
organoids, indicating improved contractile maturation of hiPSC-CMs by D10. 
Ratiometric expression of myosin light chain ventricular isoform (MYL2) over atrial 
isoform (MYL7) showed more significant increases by D10 in cardiac organoids, 
indicating improved ventricular specification of hiPSC-CMs; n=3 experiments, 10-15 
microtissues/experiment. (C,D) Shifts in gene ratios were supported by increased 
cardiac troponin I (cTnI)-positive and ventricular myosin light chain (MLC-2v)-positive 
fraction area over α-sarcomeric actinin (α-SA)-positive area (hiPSC-CM-specific areas), 
represented by low and high magnification immunofluorescent images; n=3 
microtissues. Cardiac organoids were fabricated using a developing stage cell ratio. 
hiPSC-CM- human induced pluripotent stem cell-derived cardiomyocyte. Asterisk 
represents significant difference, p<0.05. 
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process of self-assembly, hiPSC-CM spheroid spontaneous beating started after two days 
of spheroid assembly (D-2), while cardiac organoid spontaneous beating started after four 
days of spheroid assembly (D0). hiPSC-CM spheroids at D0 showed more phenotypic 
banding of α-SA-positive Z-lines than cardiac organoids, however, by D10 the cardiac 
organoids showed more enhanced organization (e.g., Z-line width) of sarcomeres than 
hiPSC-CM spheroids (Figure 3.6A). Particularly, the presence of Z-line widths greater than 
10 µm was observed more frequently among different cardiac organoids (13 out of 19; 
n=5 experiments) than in hiPSC-CM spheroids (1 out of 10; n=3 experiments) seen in 
Figure 3.17A, supporting the reproducibility of human cardiac organoids.  
To further evaluate contractile improvements in cardiac organoids, contractile 
maturation and cardiomyocyte subtype specification (i.e., ventricular) were examined. As 
an indicator of contractile maturation221 and to evaluate hiPSC-CM-specific development, 
ratiometric gene expression of adult cardiac troponin I and immature troponin I (i.e., 
TNNI3/TNNI1) revealed a significant increase in TNNI3/TNNI1 in cardiac organoids and an 
insignificant increase in hiPSC-CM spheroids from D0 to D10 (Figure 3.6B). This was 
further supported by significantly higher density of cardiac troponin I (cTnI) expression in 
the cardiac organoids than hiPSC-CM spheroids, when normalized to the α-SA-positive 
area of stained spheroid sections (Figure 3.6C, 3.17B). To examine the cardiac organoids 
for working myocardium development, ventricular myosin light chain (protein:MLC2v, 
gene:MYL2) and atrial myosin light chain (protein:MLC2a, gene:MYL7) were used for 
ratiometric gene expression. At D10 both cardiac organoids and hiPSC-CM spheroids 
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showed increased ventricular/atrial (i.e., MYL2/MYL7) expression, though cardiac 
organoids showed a significantly greater shift toward ventricular gene expression (Figure 
3.6B). In addition, the immunofluorescent expression of MLC2v showed increased 
staining density per α-SA-positive regions in cardiac organoids over hiPSC-CM spheroids 
(Figure 3.6D, 3.17C). Although both groups show spontaneous beating throughout the 
experiment, the observed enhanced sarcomere development, increased adult cardiac 
troponin I expression, and a greater ventricular shift in expression supports the 
development of hiPSC-CMs in cardiac organoids. 
Interestingly, the contraction amplitude of cardiac organoids is significantly lower 
than hiPSC-CM spheroids (0.61 ± 0.25% vs. 1.98 ± 1.2%), despite having similar 
spontaneous beat rates (cardiac organoids: 36.9 ± 8.0 beats per minute (bpm) vs. hiPSC-
CM spheroids: 33.8 ± 3.4 bpm) (Figure 3.18). The low contraction amplitude of cardiac 
organoids is possibly due to the increased extracellular matrix components (e.g., collagen) 
and interstitial cell types, resulting in a denser/stiffer construct that creates an increased 
load for cardiomyocyte contraction. This was supported by the improved contractile 
structure and gene profile in cardiac organoids despite low contraction amplitude, 
highlighting the importance of the multicellular and matrix environment for hiPSC-CM 
maturation and ventricular lineage specification seen by others.245,291 It is worth noting 
that the observed relationship between cardiomyocyte function and changes in 
cellular/ECM components is equally important to cardiac development and maturation as 
it is to cardiac pathophysiology, such as in chronic cardiac fibrosis.292,293 The previously 
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mentioned data from Figure 3.2D and 3.2E (showing decreased contraction amplitude 
with increased fibroblast number) also supports these tissue-level dynamics and offers 
evidence of possible pathological applications within a tunable cardiac organoid system. 
Human cardiac organoids display phenotypic responses to pharmacological 
compounds. For a functional cardiac organoid, the observed phenotypic structure, 
organization, and contractile development in D10 cardiac organoids must also be 
supported by demonstrated functions of fundamental characteristics of cardiac tissue. 
Given that calcium handling in cardiomyocytes is involved in electrical signal generation 
and propagation and is intimately involved in the contractile apparatus24, the explored 
improvements in contractile characteristics of cardiac organoids suggested functioning 
calcium-handling properties. Membrane calcium channels (e.g., L-type calcium channel) 
contribute to the initiation of the calcium-induced calcium-release (CICR) phenomenon in 
cardiomyocytes. Verapamil is a multi-channel blocker that causes a decreased calcium 
transient peak due to a large calcium L-type channel blockade. However, it has served as 
a false-positive arrhythmogenic drug in hERG channel based arrhythmogenic drug 
screening.69 Administration of 500 µM of verapamil resulted in a significant decrease in 
peak fluorescence and no observed arrhythmogenic activity (Figure 3.7A). This response 
validates the phenotypic functionality of L-type calcium channels to support CICR 
dynamics for contraction. The initial inward flux of calcium then binds to ryanodine 
receptors on the sarcoplasmic reticulum that release the intracellular stores of calcium 
located in the sarcoplasmic reticulum to provide enough calcium for contraction. To 
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examine the calcium release functionality of cardiac organoids, the ryanodine receptor 
Figure 3.7. Human cardiac organoids display phenotypic channel functionality and 
organotypic responses to physiological/pathological stimuli. Cardiac organoids showed 
functional calcium handling. (A) Verapamil, which blocks the L-type calcium channel, 
displayed significant phenotypic reduction of calcium transient amplitude without 
inducing arrhythmia in cardiac organoids; n=4 organoids. (B) The use of ryanodine, 
known to block the ryanodine receptor of the sarcoplasmic reticulum and reduce 
endogenous calcium release, showed a significant decrease in calcium transient 
amplitude and a significant increase time to peak calcium; n=3 organoids. (C) Blockade 
of the hERG potassium channel using E-4031 showed a significant drop in calcium 
transient peak and a significant increase in time to 50% calcium decay; n=3 organoids. 
(D) A significant increase in beat rate after application of isoproterenol indicated intact 
β-adrenergic signaling in cardiac organoids; n=5 organoids. (E) Cardiac organoids 
showed organotypic transcription responses to ischemic stimuli; n=3 experiments; 10-
15 microtissues/experiment. Cardiac organoids and hiPSC-CM spheroids showed 
increased VEGFA expression in response to ischemic stimulus. IL6 expression, a 
prominent interleukin in ischemic heart failure, increased in cardiac organoids in 
ischemia, while it was not detected in hiPSC-CM spheroids. hiPSC-CM-human induced 
pluripotent stem cell-derived cardiomyocytes. Cardiac organoids were fabricated using 
a developing stage cell ratio and were used at D10. Asterisk represents significant 
difference, p<0.05. 
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was blocked using 50 µM ryanodine. Ryanodine receptor blockade resulted in a significant 
decrease in peak calcium transient (Figure 3.7B). Also, ryanodine administration 
significantly increased time to peak calcium, indicating proper function of the ryanodine 
receptor to regulate the intracellular flux of calcium required for contraction. These 
results demonstrated the cardiac organoids recapitulate important calcium handling 
properties of working human myocardium. 
To counter the flux of calcium during contraction, potassium channels, such as the 
hERG potassium channel, play a large role in repolarization phase of the cardiac action 
potential.24 To examine the repolarization functionality of cardiac organoids, hERG 
potassium channels were blocked with 10 µM E-4031. By blocking a major potassium 
channel, repolarization is slowed, indicated by an extension in calcium transient decay 
time. Blockade of the hERG channel resulted in significantly decreased peak calcium and 
a significant phenotypic extension of the time to 50% calcium decay (Figure 3.7C). 
Together with calcium handling results, these data showed the cardiac organoids 
supported the proper development of tissue-level channel functions.  
Human cardiac organoids display phenotypic functionality under physiological 
and pathological stimuli. A series of physiologically relevant stimuli showed indications 
of a wider range of tissue-level functionality of cardiac organoids beyond drug screening 
and electrical property development. Beta-adrenergic signaling is a physiological process 
of beat rate regulation by the autonomic nervous system by catecholamines.294 Using 
video analysis of the beating rate of cardiac organoids, a beta-adrenergic agonist, 
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isoproterenol (1 µM), showed a significant increase in beat rate (Figure 3.7D). This 
validates the intact beta-adrenergic signaling pathways in hiPSC-CMs within the cardiac 
organoids for physiologically relevant stimulation. 
Despite immature characteristics of cardiac organoids compared to adult 
ventricular tissue, the presence of fundamental physiological cardiac functions provided 
a basis for exploring critical pathways involved in cardiac pathologies, supported by recent 
progress using hiPSC-CMs for cardiac pathophysiology insights.102,240,295-297 Particularly, 
cardiac organoids have potential to serve as an in vitro cardiac model for ischemic heart 
failure, which makes up the majority of cardiovascular-related disorders.298 To evaluate 
the initial response to a pathological stimulus, cardiac organoids and hiPSC-CM spheroids 
were cultured for 6 hrs in ischemia. While the VEGFA expression in cardiac organoid is 
lower than the hiPSC-CM spheroids in a normoxia environment, ischemic stimulus led to 
a significant increase in VEGF-A gene expression in the cardiac organoids to similar levels 
to that of hiPSC-CM spheroids (Figure 3.7E). Spheroids of each cell type all showed 
increases in VEGFA expression under ischemic conditions (Figure 3.19A). hiPSC-CMs and 
cFBs showed the highest levels of ischemic VEGFA expression, suggesting their dominant 
role in VEGF signaling during ischemic stress. This trend is analogous to increases in VEGF 
expression in ischemic cardiac tissue and further supports the biomimetic regulation of 
VEGFA expression in cardiac organoids.299 Furthermore, the addition of non-
cardiomyocytes into the cardiac organoids system incorporated an extended 
inflammatory response, namely, IL-6 gene expression, a prominent interleukin up-
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regulated in heart failure. After ischemic insult, IL6 expression increased significantly in 
cardiac organoids and was absent in CM spheroids (Figure 3.7E). This was attributed the 
presence of cFB in the organoids as single cell spheroid evaluation showed cFBs with the 
highest levels of IL-6 gene expression in response to ischemic stimuli (Figure 3.19B). Drug-
based and biomimetic stimulation of cardiac organoids can provide a fundamental and 




With inspiration from major events in coronary vasculogenesis and a defined 
method of microtissue fabrication, we have developed a robust platform to fabricate 
vascularized human cardiac organoids that recapitulated the lumenized vascular network 
of the developing myocardium, supported hiPSC-CM development and demonstrated 
fundamental cardiac tissue-level functions. In contrast to the common organoid 
fabrication approach of directed differentiation of embryoid bodies (EBs), the dynamic 
cellular organization surrounding coronary vasculogenesis provided the developmental 
basis for the use of defined cell types to develop a tunable cardiac organoid system. This 
platform provides a consistent and efficient method of human cardiac organoid 
fabrication (e.g., 100% beating, consistent cellular organization, and minimal size 
variability) that supports high throughput applications (e.g., drug testing) in comparison 
to cardiovascular EB differentiation, where there is high variability in size and morphology 
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with only ~2%-15% of EBs showing contractile beating.236 Furthermore, while hiPSC-CMs 
have been extensively used to model cardiac disorders, other cardiac cell types, such as 
cardiac fibroblasts and endothelial cells, are involved in many cardiac pathologies.300,301 
The use of a defined cardiac cell mixture for cardiac organoid formation is advantageous 
by providing an adaptable system to incorporate and investigate the contribution of each 
cardiac cell type, matrix materials, additional factors, and other physiological system 
relationships (e.g., immunological cell types) to cardiac developmental/pathological 
dynamics at a tissue/organ level. 
In addition, similar to developing cardiomyocytes, the spontaneous beating 
property of hiPSC-CMs supports contractile development and provided the source of 
pacing in the cardiac organoids. To obtain adult stage ventricular maturation, in which 
cardiomyocytes do not beat spontaneously, exogenous pacing may be required. 
Interestingly, recent optimizations in stem cell-derived cardiomyocyte media suggest that 
mature contractile characteristics, such as positive force-frequency, can be achieved 
through the supply of defined growth factors.243 Looking toward future applications, 
cardiac organoids with lumenized vascular networks provide a tunable foundation to 
develop future pre-vascularized, injectable vehicles for regenerative cell therapy to treat 
heart failure. In summary, the human cardiac organoid technology presented here 
provides a robust platform for the development of the next generation of hiPSC-based 




Materials and Methods 
Cell culture. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-
CMs) (iCell Cardiomyocytes, Cellular Dynamics International-CDI, Madison, WI, USA) were 
cultured according to the manufacturer's protocol. Briefly, hiPSC-derived cardiomyocytes 
were plated on 0.1% gelatin coated 6-well plates in iCell Cardiomyocyte Plating Medium 
(CDI) and incubated at 37 °C in 5% CO2 for 4 days. Two days after plating, the plating 
medium was removed and replaced with 4 mL of iCell Cardiomyocytes Maintenance 
Medium (CDI). After 4 days of monolayer pre-culture, cells were detached using trypLE 
Express (Gibco Life Technologies, Grand Island, NY) and prepared for spheroid/organoid 
fabrication. Human cardiac ventricular fibroblasts (cFBs) (Lonza, Basel, Switzerland) were 
cultured in FGM-3 media (Lonza) were used at passage 3-4 for spheroid/organoid 
fabrication. Human umbilical vein endothelial cells (HUVECs) (Lonza) were cultured in 
EGM-2 media (Lonza) and were used at passage 2-3 for spheroid/organoid fabrication. 
Human adipose-derived microvascular endothelial cells (HAMECs) (kind gift from Dr. 
Michael Yost) and were cultured in EGM-2 media (Lonza) and were used at passage 5-6 
for organoid fabrication. Human adipose-derived stem cells (hADSCs) (Lonza) were 
cultured in low glucose Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum 
(FBS) and 1% penicillin-streptomycin, 1% glutamine and 1% antimycin (Gibco Life 
Technologies, Grand Island, NY). hADSCs were used at passage 3-4 for spheroid/organoid 
fabrication. For cFBs, hADSCs, and HUVECs, media was changed every 2 days and were 
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passaged using trypLE Express (Gibco) at >80% confluency. An array of media were 
evaluated to best support consistent organoid formation and culture, shown in Figure 
3.17. The optimal culture media for viable cardiac organoids was comprised of a 
ratiometric combination of cell-specific media reflecting the cell ratio of the organoid. In 
organoid media, CDI hiPSC-CM Maintenance Media (supplied without glucose) was 
substituted with glucose-containing DMEM/F12 media with 10% FBS and 1% non-
essential amino acids (Gibco). 
Organoid and spheroid fabrication. As described in our previous publication45, the 
agarose hydrogel molds were prepared using 2% agarose (Sigma Aldrich, St. Louis, MO) 
and master micro-molds from Microtissues, Inc (Providence, RI) as negative replicates to 
create non-adhesive agarose hydrogels molds containing 35 microwells with hemispheric 
bottoms (800 m diameter, 800 m deep) to facilitate the formation of spherical 
microtissues. Molds were soaked in cell/organoid specific media prior to microtissue 
fabrication. Working cell suspensions of each cell type were used at ~4.0 x 106 cells/mL to 
make organoid cell ratio mixtures and mixed with 1 volume media for a final 
concentration of ~2.0 x 106 cells/mL. Approximately 75 µl of the cell suspension was 
pipetted into each agarose mold. After the cells settled into the recesses of the mold (10 
min), additional media was added to submerge the molds in an 8-well plate and 
exchanged every 2 days for the length of the experiment (10 days). Day 0 (D0) of the 
experiment was marked after 4 days of spheroid assembly. A scheme of the experimental 
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timeline can be found in Figure 3.8. TUNEL staining for apoptotic nuclei revealed that D0 
cardiac organoids maintained high viability throughout the microtissue (Figure 3.10). 
Contraction analysis of beating spheroids. Videos of spontaneously beating 
spheroids from each group were recorded at ~37 °C for each condition using a Carl Zeiss 
Axiovert A1 Inverted Microscope and Zen 2011 software (Zeiss, Göttingen, Germany). 
Videos were converted to a series of TIFF format pictures by Adobe Premiere (Adobe, San 
Jose, CA). Threshold edge-detecting in ImageJ software (National Institutes of Health) was 
used on high contrast spheroid picture series and graphed to realize beating profiles of 
fractional area change (i.e., contraction amplitude), from which beats per minute and 
contraction amplitude was calculated. Contraction amplitudes were calculated as the 
percent change in fractional area change amplitude between contraction and relaxation. 
Immunofluorescent analysis. Freshly collected spheroids were flash frozen in 
Tissue-Tek OCT compound (Sakura, Torrance, CA). Embedded spheroids were 
cryosectioned into 7 µm sections onto glass slides. The sections were fixed with cooled 
acetone (-20 °C) for 10 min. After washing (2 times at 5 min) in PBS with 0.1% Triton X-
100 (PBST) (Sigma), blocking buffer was made with 10% serum corresponding to host 
species of secondary antibody in PBST and added to sections for 1 hr at room 
temperature. Sections were incubated with primary antibody diluted in PBST (1:200) 
overnight at 4 °C or 2 hrs at room temperature: rabbit anti-laminin (Sigma), rabbit-anti 
collagen type I (Abcam), rabbit anti-fibronectin (Abcam), mouse anti-alpha sarcomeric 
actinin (Abcam), rabbit anti-cardiac troponin I – cTnI (Abcam), rabbit anti-MYL2 (MLC-2v) 
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(Abcam), rabbit anti-vimentin (Abcam), mouse anti-CD31 (BD Biosciences, San Jose, CA), 
rabbit anti-von Willebrand factor (vWF) (Abcam). After washing in PBST (2 times at 5 min), 
sections were incubated with complement secondary antibodies diluted in PBST for 1 hr 
at room temperature: goat anti-mouse Alexa Fluor 546 (Thermo), goat anti-rabbit Alexa 
Fluor 647 (Jackson ImmunoResearch, West Grove, PA). After washing in PBST (2 times at 
5 min), nuclei were counterstained with DAPI (Molecular Probes/Invitrogen, Eugene, OR) 
diluted in PBST for 15 min at room temperature. Following the final wash procedure 
(PBST, 2 times at 5 min), glass cover slips were added to the slides using Fluoro-Gel 
(Electron Microscopy Sciences, Hatfield, PA). TCS SP5 AOBS laser scanning confocal 
microscope (Leica Microsystems, Inc., Exton, PA) was used for imaging. Imaris software 
(Bitplane, Zurich, Switzerland) was used to reconstruct z-stacked confocal images for 3D 
visualization. Fluorescent protein expression was calculated as the antibody-positive 
fluorescence area coverage: endothelial density was calculated as vWF-positive covered 
area divided by spheroid area, lumens per organoid a was calculated as the number of 
vWF-positive ring-shaped structures with adjacent DAPI-stained nuclei per organoid, 
vimentin density was the ratio of vimentin-positive area within the α-SA-positive area, 
ECM fraction area was calculated as the ECM-stain positive area divided by the spheroid 
area, and the relative contractile protein amount was calculated as the ratio of cTnI or 
MLC-2v area to total α-SA covered area. Each analysis consisted of high resolution images 
at 400X total magnification of 3-5 spheroids. Hematoxylin and eosin-stained embryonic 
mouse heart sections were a kind gift from the lab of Dr. Russell Norris. 
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TUNEL staining for apoptosis. Roche In Situ Cell Death Detection Kit (Sigma) was 
used to visualize the viability of cells in frozen sections of cardiac organoids based on the 
Roche protocol. Briefly, cardiac organoid frozen sections were fixed with 4% 
paraformaldehyde in PBS for 20 min at room temperature. Following washing in PBS for 
30 minutes, samples were incubated in a permeabilization solution (0.1% Triton X-100 
and 0.1% sodium citrate in PBS) for 2 minutes on ice. Then 50 µl of the TUNEL reaction 
mixture were added to samples and incubated at 37 °C for 1 hr. After washing in PBS (2 
times at 5 min), nuclei were counterstained with DAPI (Molecular Probes/Invitrogen) 
diluted in PBS for 15 min at ambient temperature. Following the final wash procedure 
(PBS, 2 times at 5 min), glass cover slips were added to the slides using Fluoro-Gel 
(Electron Microscopy Sciences). TCS SP5 AOBS laser scanning confocal microscope (Leica 
Microsystems) was used for imaging. TUNEL-based viability index was calculated as [1 – 
(TUNEL-positive area / DAPI-positive area)]. 
Gene expression with qRT-PCR. Total RNA was isolated according to the kit and 
protocol of an RNeasy Micro Kit (Qiagen, Vinlo, Netherlands) with the addition of the 
Homogenizer Columns (Omega Biotek, Norcross, GA) during the homogenization step for 
spheroids. For each group, a minimum of 10 spheroids were used for RNA isolation. At 
least 25 ng of total RNA for each group was subjected to cDNA synthesis using the Bio-
Rad (Hercules, USA) iScript cDNA synthesis kit. qRT-PCR step was performed using 
validated Life Technologies Taqman primers (Thermo Fisher Scientific) in 10 μl reactions 
for targeted genes: ACTB (Hs01060665_g1), GAPDH (Hs02758991_g1), IL6 
 93 
(Hs00985639_m1), KDR (VEGFR2, Hs00911700_m1), MYL2 (Hs00166405_m1), MYL7 
(Hs01085598_g1), TNNI1 (Hs00913333_m1), TNNI3 (Hs00165957_m1), VEGFA 
(Hs00900055_m1). Data was normalized as the change in cycle threshold (Ct) to the 
geometric mean of GAPDH and ACTB (dCt) and analyzed using, mRNA expression = 2^(-
dCt). Data was then averaged across n=3 experiments. 
Calcium transient imaging. Life Technologies’s Fluo-4 Direct Calcium Assay Kit (Life 
Technologies, Carlsbad, CA) was used to label calcium in the whole organoids based on 
the manufacturer protocol. Briefly, organoids stained with a working solution of 1:1 
calcium dye solution to media and incubated at 37 °C, 5% CO2, 20% O2 for 30 min. Carl 
Zeiss Axiovert A1 Inverted Microscope completed with GFP fluorescence imaging capacity 
(Zeiss) was used to collect the videos of the calcium transient of whole spheroids with a 
capture rate of 20 frames per second. Finally, we used Zen 2011 software (Zeiss) to 
convert videos to a series of TIFF format pictures. Mean gray value of the whole organoid 
calcium transient (controlled for area for pre- and post- treatment) was measured using 
ImageJ software (National Institutes of Health) to construct calcium transient profiles. 
Normalized F/F0 was calculated as the peak calcium fluorescence (F) divided by the start 
fluorescence level (F0), then divided by the F/F0 of the baseline transient before 
treatment. Time to peak calcium (sec) was calculated as the difference in time between 
the peak calcium and the start of the calcium transient. Time to 50% calcium decay (sec) 
was calculated as the difference in time between the start of the calcium transient and 
the half-peak (F50) of the calcium decay. 
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Evaluation of putative vasculature. Oxygen reduction studies were performed at 
10% O2 in a hypoxia chamber (C-Chamber, BioSpherix, Parish, NY) for a duration of 10 
days. Media was exchanged every 2 days. Microtissues were embedded in OCT, 
cryosectioned, and Roche In Situ Cell Death Detection Kit (Sigma) was used to visualize 
the viability of cells in frozen sections of cardiac organoids based on the Roche protocol. 
Macrotissue assembly was performed in agarose-coated (non-adhesive) 96-well plates. 
Five cardiac organoids (developing stage cell ratio) were placed in each well and culture 
for 10 days until the macrotissues had an appreciable Z-dimension, observed by pipette 
agitation. Organoid aggregate macrotissues were embedded in OCT and cryosectioned 
for immunofluorescent analysis. Media was exchanged every day. 
Pharmacological, physiological, and pathological stimulus. Pharmacological 
compounds were used to block channels of human cardiac organoids and were 
performed on single organoids in ultra low-adhesive GravityTRAP Plates (InSphero, 
Schlieren, Switzerland) at 37 °C. Freshly prepared stock solutions of verapamil (Sigma), 
ryanodine, and E-4031 were diluted in the calcium buffer provided in the calcium staining 
kit (Life Technologies). Verapamil (0.5 µM), ryanodine (50 µM), and E-4031 (10 µM) added 
to the organoids and calcium signal was video captured after 20 mins. Isoproterenol (1 
µM) was added for 10 mins before bright field videos were captured. For ischemic 
stimulus, microtissues were rinsed in low glucose DMEM (1 g/L) (Gibco) and placed in 
agarose molds in serum-free, low glucose (1 g/L) DMEM and 1% O2 (BioSpherix) for 6 hrs 
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to examine the initial response. Controls were cultured at normoxia in cell/organoid-
specific media. 
Statistics Analysis. Differences between experimental groups were analyzed on 
JMP Pro 12 Statistical software (SAS, Cary, NC) using Student’s t-test, matched pairs 
comparison, one-way ANOVA, and two-way ANOVA with Tukey’s post-hoc test, and 







Figure 3.8. Experimental timeline of human cardiac organoids. Microtissues (cell type-
specific spheroids and cardiac organoids) were pre-cultured for 4 days until 
experimental Day 0 (D0). Human cardiac organoids began synchronized, spontaneous 
beating on D0 and continued throughout the length of the experiment. Microtissues 





Figure 3.9. The ratio of cells in cardiac organoids influences contractile development. 
Developing stage ratio organoids, which contains more cardiomyocytes, supported 
improved sarcomere formation (α-SA-positive with sarcomeric banding) in contrast to 
adult stage ratio organoids at D10 (α-SA-positive without sarcomeric banding); green-





Figure 3.10. Culture media screening using TUNEL staining (green) for apoptotic nuclei 
of D0 cardiac organoids showed significantly better viability index throughout the 
microtissues using ratiometric media compared to DMEM/F12 with FBS cultured; n=3-
4 organoids. The ratiometric media was a combination of cardiomyocyte media 
(DMEM/F12, 10% FBS, 1% non-essential amino acids), fibroblast media (Lonza FGM-
3), and endothelial cell media (Lonza EGM-2) corresponding to the developing cell 
ratio. Blue – DAPI nuclear stain. Cardiac organoids with a developing stage cell ratio 





Figure 3.11. Confocal imaging of immunofluorescently stained whole cardiac organoids 
(D10) show lumenized vascular network. (A) Method schematic shows that large Z-
stack confocal images were collected; serial images were taken every 5 µm across 40 
µm of Z depth. (B) Serial vWF (red) and DAPI (blue) images (XY plane) every 5 µm 
starting at 40 µm from the top of the spheroids show endothelial cell organization. 
Arrows indicate regions showing lumen-like structures in X, Y, and Z perspectives seen 




Figure 3.12. Analysis of individual cell types and cardiac organoids regulation of 
angiogenic gene expression in human cardiac organoids at D10. (A) VEGFA gene 
expression in cardiac organoids was significantly lower than spheroids of hiPSC-CMs, 
cFBs, and hADSCs alone, and significantly higher than that of HUVECs. (B) HUVECs 
showed significantly higher levels of VEGFR2 gene expression than all other groups, 
while cardiac organoids and hiPSC-CMs showed higher expression than cFBs and 
ADSCs. Differences in VEGFA expression between organoids and a ratiometric 
theoretical organoid suggested self-regulation of VEGFA signaling between VEGF 
providers (hiPSC-CMs, cFBs, hADSCs) and VEGF receivers (HUVECs). Theoretical 
organoid expression levels were calculated based on ratiometric combination of gene 
expression of the organoid ratio of cell types (50% hiPSC-CM, 29% cFBs, 14% HUVECs, 
and 7% hADSCs). Cardiac organoids were fabricated using a developing stage cell ratio; 
n=3 experiments; 10-15 microtissues/experiment. hiPSC-CM-human induced 
pluripotent stem cell-derived cardiomyocyte, cFB-human adult ventricular cardiac 
fibroblast, HUVEC-human umbilical vein endothelial cell, hADSC-human adipose-
derived stem cell. * significantly higher than remaining, ** significantly different than 





Figure 3.13. Evaluation of putative vasculature using an oxygen-reduced environment. 
Cardiac organoids were placed in 21% O
2
 (control) or 10% O
2
 (oxygen reduction) 
starting at D0 until D10 (D0-D10; before formation of putative vasculature) or D10 until 
D20 (D10-D20; after formation of putative vasculature). Compared to time-matched 
controls at D10 and D20 and vascularized organoids with oxygen reduction, cardiac 
organoids without putative vasculature under oxygen reduction showed high presence 
of TUNEL apoptosis staining (green); blue-DAPI nuclear stain. Cardiac organoids were 




  Figure 3.14. Evaluation of putative vasculature using macrotissue assembly. After 10 
days of aggregation of five D10 cardiac organoids, the macrotissue reached dimensions 
beyond the oxygen tension range of a 100-200 µm radius microtissues. Across all 
repeats, there were minimal TUNEL-positive apoptotic nuclei (green); blue-DAPI. 
Endothelial vWF-positive (red) staining showed extensive regions of connected, 
immunostained endothelial cells (i.e., networks) across the newly formed macrotissue. 
Green-alpha sarcomeric actinin, α-SA. Cardiac organoids were fabricated using a 





Figure 3.15. Endothelial cell source affect structural functionality. Cardiac organoids 
made with human umbilical vein endothelial cells (HUVECs) at a developing stage cell 
ratio with human adipose-derived stem cells (hADSCs) show consistently higher 
density of vWF-positive (red) cells on D10 compared to cardiac organoids made with 
human adipose-derived microvascular endothelial cells (HAMECs) at the same ratio, 
while cardiomyocyte organization (green, alpha sarcomeric actinin α-SA-positive) is 
consistent between organoids. Both HUVECs and HAMECs show evidence of 




  Figure 3.16. Both hiPSC-CM spheroids and cardiac organoids showed 
immunofluorescent expression of laminin that did not change significantly over time. 
Quantification of ECM components was based on the ratio of ECM-positive covered 
area divided by total spheroid area; n=3-6 microtissues. Cardiac organoids with a 
developing stage cell ratio were used for media screening. hiPSC-CM-human induced 





Figure 3.17. Human cardiac organoids support contractile development of hiPSC-CMs. 
(A) Cardiac organoids at D10 showed a higher occurrence of the observed extended Z-
line width (> 10 µm) across different spheroids and experiments. hiPSC-CM spheroids: 
n=3 experiments; cardiac organoids: n=5 experiments. (B) Cardiac organoids showed 
increased adult cardiac troponin I (cTnI)-positive and (C) ventricular myosin light chain 
(MLC-2v)-positive fraction area over α-sarcomeric actinin (α-SA)-positive area (hiPSC-
CM-specific areas) at D10, represented by low and high magnification 
immunofluorescent images, n=3 microtissues. hiPSC-CM-human induced pluripotent 
stem cell-derived cardiomyocyte. Cardiac organoids were fabricated using a developing 





Figure 3.18. Functional analysis of human cardiac organoids and hiPSC-CM spheroids. 
(A) At D10, cardiac organoids showed a significantly lower contraction amplitude (i.e., 
fractional area change) than spheroids of 100% hiPSC-CM (hiPSC-CM spheroids); n=28-
41 microtissues. (B) Cardiac organoids and hiPSC-CM spheroids showed similar beat 
rates (beats per minute) on D10; n=23-31 microtissues. Cardiac organoids were 






Figure 3.19. Response of individual cell types to ischemia on D10. (A) hiPSC-CM and cFB 
spheroids showed significant increases in VEGFA gene expression in response to 6 hrs 
of ischemia (1 g/L glucose, serum-free, 1% O2), contributing to the significant increase 
in cardiac organoid expression. (B) cFB-only spheroids showed significant increase in IL6 
gene expression. Cardiac organoids were fabricated using a developing stage cell ratio; 
n=3 experiments; 10-15 microtissues/experiment. Asterisk represents significant 
difference with control, p <0.05. 
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CHAPTER FIVE 
FUTURE DIRECTION AND OUTLOOK 
 
 The development of biomimetic models for cardiac tissue requires the 
appropriate understanding of the biological system and necessary strategies to 
recapitulate those processes. Throughout this exploration, I gained a unique perspective 
into multiple dimensions of biomimicry, from extracellular matrix interactions, to 
electrically compatible strategies, and mechanisms of multi-cellular self-assembly. With 
an understanding of the strengths of each biomimetic approach, these strategies can be 
leveraged for applications in basic research, drug discovery, and cell therapy. As heart 
failure poses an imminent challenge to human health, future directions will consist of 
adapting these approaches to enhance our understanding of cardiac tissue physiology 
and self-assembly, to model cardiac pathological conditions, and to advance the current 
cell delivery vehicle for heart repair. 
 The exploration presented here contributes to the growing knowledge of scaffold-
based and scaffold-free tissue-engineered constructs. With extracellular matrix 
remodeling being a hallmark of heart failure pathology, the use of tunable materials, such 
as functionalized alginate or electrically conductive silicon nanowires, may provide an 
adaptable tool to investigate microenvironment-dependent changes in cell behavior. 
Furthermore, given the heterogeneous cell-cell interactions, a multicellular 3D cardiac 
organoid model not only provides a robust platform to investigate the role of individual 
cells but also provides a tissue-level perspective that incorporates innumerable variables, 
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such as synergistic signaling mechanisms between cells, to more accurately model the 
complex multicellular environment of heart tissue. This avoids false-positive results from 
single cell or 2D systems that are later counteracted, for example, by inhibitory signaling 
from other cell types within a tissue/organisms. In the end, improvements in the 
treatment of heart failure depends on relevant and accurate models. Pursuing a better in 
vitro cardiac tissue model using hiPSC technology will allow for a humanized, personalized 
model that can avoid the disadvantages of single cell systems and translational 
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